

Markus Zeitlinger

M.D., Assoc. Prof. Priv.Do.

Date of birth: 09/04/1975

Languages: German, English

Married, two children

Medical University of Vienna, Department of Clinical Pharmacology

A-1090 Vienna, Austria

Phone Number: +431 40400 29810

Email: markus.zeitlinger@meduniwien.ac.at



Biosketch

Markus Zeitlinger studied medicine at the Medical University of Vienna and graduated in 2000. He completed his training as specialist in Internal Medicine and Clinical Pharmacology and advanced to his main current position as Head of the Department of Clinical Pharmacology. In 2007 he received his post-graduate diploma in Clinical Research. Beside clinical trial design his scientific interests cover antimicrobial agents with focus on early phases of clinical research and pharmacokinetics/pharmacodynamics (PK/PD). He has published over 350 peer reviewed publications and book chapters in particular in the areas of antimicrobial agents, vaccines and imaging and is ad hoc reviewer of over 30 journals. As scientific expert to the European Medicines Agency (EMA) he was actively involved in more than 450 scientific advice procedures given by the agency, including many rapid scientific advice procedures during the Covid-19 pandemic. Furthermore he holds key positions in several national and international scientific societies as well as in a number of national and six European research consortia. International functions include e.g. chairing of the PK/PD working group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) while national functions include membership at Scientific Advisory Board (Wissenschaftlicher Ausschuss) or Drug Board of Austrian Ministry of Health (Arzneimittelbeirat). He is also member of the Senate of the Medical University of Vienna.

Academic Career

28.01.2000	Graduation M.D.
Since June 2007	Section Head Clinical Pharmacokinetics/Pharmacogenetics and Imaging, Department of Clinical Pharmacology, Medical University of Vienna
11.10.2007	Post Graduate Diploma in Clinical Research
16.05.2008	Associate Professor of Clinical Pharmacology (Venia docendi for Clinical Pharmacology, "Habilitation")
01.08.2010	Board certification in Internal Medicine
03.06.2011	Board certification in Clinical Pharmacology
Since October 2015	Head of Department of Clinical Pharmacology, Medical University of Vienna
Since October 2022	Regular Member of the Senate of the Medical University of Vienna

Academic Achievements

Publications: 370 publications in peer reviewed journals, 6 book chapters ([Appendix A](#)).
orcid.org/0000-0002-1873-3953

Contributions at scientific conferences: more than 350 presentations, posters and chairs at national and international conferences, out of these 90 invited lectures.

National and International Positions:

May 2005 – present	Expert of the “Committee for Medicinal Products for Human Use” (CHMP)
March 2011 – present	Member of Steering Committee Society for Pharmaceutical Medicine (GPMed), since 2017 Vicepresident
August 2014 – present	Member of the Scientific Drug Advisory Board of Austrian Ministry of Health (Wissenschaftlicher Ausschuss)
October 2016-present	Member of the Committee for Drug Prescription Requirement of the Austrian Ministry of Health
December 2016-present	Member of the Steering Committee International Society of Anti-Infective Pharmacology (ISAP)
April 2018-present	Chair ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
September 2016-present	Ludwig Boltzmann Institute (LBI) for Applied Diagnostics, Clinical Workpackage Leader
Juli 2020-present	Director of Clinical Research “TIPAT” EU-Project
January 2020-present	Lay judge of national administration court (Bundesverwaltungsgericht)
June 2020-present	Associate Member of the Executive Committee European Association for Clinical Pharmacology and Therapeutics (EACPT)
January 2021-present	National coordinator of “VACCELERATE” EU-Project
January 2021-present	Group Leader Quantitative Clinical Imaging (QCI) Node, Medical University of Vienna
April 2021-present	Member of the Scientific Advisory Board of the “Wiener Gesundheitsverbund”
January 2021-present	Executive Board member of the Comprehensive Center for Infection Medicine of Medical University of Vienna
July 2022-present	Assessor for Vaccine Associated Side Effects for Austrian Ministry of Health (Sachverständiger)
December 2022-present	Member of the Drug Board of Austrian Ministry of Health (Arzneimittelbeirat)
January 2023-present	Expert of Global Antibiotic Research & Development Partnership (GARDP)
July 2023-present	Member Review Panel Swiss National Science Foundation / NCCR AntiResist
March 2024-present	Coordinator of the Pandemic Preparedness Platform Austria
since 2005	numerous involvements in organizational and scientific committees of international and national symposia and congresses

Past positions:

2007 – 2013	Section Editor International Journal of Clinical Pharmacology and Therapeutics
2011 – 2018	Member of Steering Committee VKIpha (Annual German Congress on Clinical Pharmacology)
2010 – 2018	Chair Working group PK/PD of the Paul Ehrlich Gesellschaft für Chemotherapie e.V
2014 – 2015	Member of the Ethics Committee Medical University of Vienna
2016 – 2020	Chair Section of Clinical Pharmacology, Austrian Pharmacological Society (APHAR)
2017-2021	Member of the Executive Committee European Association for Clinical Pharmacology and Therapeutics (EACPT)
2017-2021	Board member Austrian Society of Internal Medicine (ÖGIM)
2016-2022	Council Member of the Federation of European Pharmacological Societies (EPHAR)
2022	Guest Associate Editor “Frontiers in Translational Pharmacology”
2021-2023	Member of the Safety Board of the National Vaccine Advisory Committee
2021-2023	Advisor to the Austrian National Health Board (“Oberster Sanitätsrat”)
2019-2023	Managing Editor European Journal of Clinical Pharmacology
2020 - 2022	Editorial Board “Microorganisms”

Memberships in scientific societies:

International Society of Anti-Infective Pharmacology (ISAP)
Österreichische Pharmakologische Gesellschaft (Austrian Pharmacological Society, APHAR)
Österreichische Gesellschaft für antimikrobielle Chemotherapie (ÖGACH, Austrian Society of Antimicrobial Chemotherapy)
Österreichische Gesellschaft für Infektionskrankheiten (ÖGI, Austrian Society of Infectious Diseases)
Paul Ehrlich Gesellschaft für Chemotherapie e.V. (PEG)
European Society of Clinical Microbiology and Infectious Disease (ESCMID)
ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
Gesellschaft für Pharmazeutische Medizin (GPMed, Society for Pharmaceutical Medicine)
European Association for Clinical Pharmacology and Therapeutics (EACPT)
Federation of European Pharmacological Societies (EPHAR)
Österreichische Gesellschaft für Innere Medizin (ÖGIM, Austrian Society of Internal Medicine)
Alumni Club Medical University of Vienna
American Society for Clinical Pharmacology and Therapeutics (ASCPT)
Verein zur Förderung von Wissenschaft und Forschung, General Hospital Vienna (VFWF)
Österreichische Plattform für Personalisierte Medizin (ÖPPM)

Participation in Task Forces:

2017-2022	National task force for implementation of the Clinical Trial Regulation in Austria (CTR)
2017-present	Task force of the Medical University of Vienna for Translational Medicine and Therapeutics (CTMT), Medical University of Vienna Main responsible for planning of the Phase I/II Unit of the CTMT
2019-present	Task force of the Medical University of Vienna for the Centre of Technology Transfer

2020-present Task Force Ignaz-Semmelweis Centre for Infection Medicine
2022-present Vienna Prevention Study

Peer reviewed grants since 2012 (total > 6.500.000 Euro):

2014-2018, Grant of the European IMI program, “New Drugs 4 Bad Bugs” (COMPACTE MAGNET)

2015-2016, Grant of the Austrian National Bank, Cerebral Microdialysis for Determination of Brain Penetration of Antibiotics

2017-2018, KLIF/FWF, Validation and Optimization of PK/PD Development Pathways of Antibiotics

2019-2023, H2020-MSCA-ITN-2019, Marie S. Curie-Actions –Training Networks for “Training towards Personalized Antibiotic Treatment” (TIPAT)

2019-2024, Grant of the European IMI2 JU AMR Accelerator program: H2020-JTI-IMI2-2018-16-01 (RespiriTB)

2019-2024, Grant of the European IMI2 JU AMR Accelerator program: H2020-JTI-IMI2-2018-16-02 (RespiriNTM)

2019-2021, Grant of the European IMI2 JU AMR Accelerator program: H2020-JTI-IMI2-2018-16-04 (AB-DiRecT)

2019-2024, Grant of the European IMI2 JU AMR Accelerator program: H2020-JTI-IMI2-2018-16-07 (GNA-NOW)

2021, VACCELERATE Grant of HORIZON 2020 – The framework program for research and development

Further third party funding since 2012:

Total > 4.500.000 (e.g. Affiris, Pfizer, Alfa Wassermann, Nabriva, Gebro, Novartis, GSK, Shionogi, Roche, Apeptico, Scarletred, APEIRON Biologics)

Editorial positions Scientific journals:

November 2017-present	Editorial Board “Pharmainformation”
September 2019-present	Editorial Board Clinical Pharmacokinetics
September 2019-present	Scientific Committee of Clinical Microbiology and Infection
January 2021 – present	Scientific Board “Spectrum Oncology”
January 2022 – present	Associate Editor “Frontiers in Pharmacology”
January 2023-present	Editorial Board “Journal of Antimicrobial Chemotherapy”
July 2023-present	Advisory Editor European Journal of Clinical Pharmacology

Reviewer for International Journals (alphabetical order):

Acta Ophthalmologica
Advanced Drug Delivery Reviews
African Journal of Microbiology Research
Annals of Clinical Microbiology and Antimicrobials
Annals of Internal Medicine
Annals of the Rheumatic Diseases
Antibiotics
Antimicrobial Agents and Chemotherapy
APMIS
Basic & Clinical Pharmacology & Toxicology
British Journal of Clinical Pharmacology
Chemotherapie Journal
Clinical Infectious Diseases

Clinical Microbiology and Infection
 Clinical Pharmacokinetics
 Clinical Therapeutics
 CMI Communications
 Critical Care Medicine
 Drugs
 European Journal of Clinical Investigation
 European Journal of Clinical Pharmacology
 European Journal of Pharmaceutical Sciences
 Frontiers in Pharmacology
 Frontiers Pharmacology
 Generics and Biosimilars Initiative Journal
 Infection
 International Journal of Antimicrobial Agents
 International Journal of Clinical Pharmacology and Therapeutics
 International Journal of Clinical Practice
 Journal of Antimicrobial Chemotherapy
 Journal of Basic Microbiology
 Journal of Pharmacology and Experimental Therapeutics
 Lancet Infectious Diseases
 Nature communications
 Ophthalmic Research
 Peritoneal Dialysis International
 Pharmaceutics
 Planta Medica
 PLoS Computational Biology
 Regulatory Toxicology and Pharmacology
 Skin Pharmacology and Physiology
 The Journal of Clinical Pharmacology
 Thrombosis and Haemostasis
 Tuberculosis
 Wiener Klinische Wochenschrift

Reviewer for national and international societies and funding agencies

Since 2017 Reviewer ESCMID Program Committee
 Since 2020 Reviewer Bürgermeister Fonds Wien
 Since 2021 Reviewer BMBF funding initiative for clinical trials
 Since 2022 Reviewer for Austrian Ministry of Health "Sachverständiger in Impfschadensfällen"
 Since 2023 Advisor Integrate-IMP board
 Since 2023 NCCR AntiResist Switzerland
 Since 2024 Swiss National Science Foundation (SNFS)
 Since 2025 Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

Award and honoree appointments:

2012 Lifetime award: Heribert-Konzett-Award of Austrian Society of Clinical Pharmacology (APHAR)
 2024 ESCMID Fellow: for professional excellence and outstanding service to the profession and society (European Society of Clinical Microbiology and Infectious Diseases)

Teaching:

Involvement in over 120 University lectures and courses
Supervision of 16 doctoral thesis (postdoc) and 45 diploma or master thesis
since 2009 Teacher at the Master of Public health, MUW
since 2022 Teacher at the Master of Molecular Precision Medicine

Clinical study experience:

since 2001 Conducting over 150 clinical studies including first in men studies as well as
all phases of clinical drug development
1/2024 last GCP training and test

Data safety Monitoring Board membership:

Since 2018: Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for
intermittent preventive treatment of malaria in HIV-infected pregnant women
Since 2020: Independent Scientific and Ethics Advisory Board (ISEAB) of EU-RESPONSE
Since 2020: Member/chair of DSMB of 3 different “first in man” studies



10.3.2025

Publication List:

- 1) Brunner M, Stabeta H, Moller JG, Schrolnberger C, Erovic B, Hollenstein U, **Zeitlinger M**, Eichler HG, Muller M. Target site concentrations of ciprofloxacin after single intravenous and oral doses. *Antimicrob Agents Chemother*. 2002 Dec;46(12):3724-30.
- 2) Joukhadar C, Klein N, Dittrich P, **Zeitlinger M**, Geppert A, Skhirtladze K, Frossard M, Heinz G, Muller M. Target site penetration of fosfomycin in critically ill patients. *J Antimicrob Chemother*. 2003 May;51(5):1247-52.
- 3) Langer O, Mitterhauser M, Brunner M, **Zeitlinger M**, Wadsak W, Mayer BX, Kletter K, Muller M. Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. *Nucl Med Biol*. 2003 Apr;30(3):285-91.
- 4) **Zeitlinger M**, Marsik C, Georgopoulos A, Muller M, Heinz G, Joukhadar C. Target site bacterial killing of ceftazidime and fosfomycin in critically ill patients. *Int J Antimicrob Agents*. 2003 Jun;21(6):562-7.
- 5) **Zeitlinger M**, Muller M. Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis. *Wien Med Wochenschr*. 2003;153(11-12):250-4.
- 6) **Zeitlinger M**, Dehghanyar P, Mayer BX, Schenk BS, Neckel U, Heinz G, Georgopoulos A, Muller M, Joukhadar C. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. *Antimicrob Agents Chemother*. 2003 Nov;47(11):3548-53.
- 7) Sauermann R, **Zeitlinger M**, Erovic BM, Marsik C, Georgopoulos A, Muller M, Brunner M, Joukhadar C. Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model. *Int J Antimicrob Agents*. 2003 Dec;22(6):574-8.
- 8) Traunmuller F, **Zeitlinger M**, Stoiser B, Lagler H, Abdel Salam HA, Presterl E, Graninger W. Circulating tuberculostearic acid in tuberculosis patients. *Scand J Infect Dis*. 2003;35(11-12):790-3.
- 9) Pfausler B, Spiss H, Dittrich P, **Zeitlinger M**, Schmutzhard E, Joukhadar C. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. *J Antimicrob Chemother*. 2004 May;53(5):848-52.
- 10) Bellmann R, Kuchling G, Dehghanyar P, **Zeitlinger M**, Minar E, Mayer BX, Muller M, Joukhadar C. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. *Br J Clin Pharmacol*. 2004 May;57(5):563-8.
- 11) **Zeitlinger M**, Graninger W, Joukhadar C. Pharmacokinetics of the macrolides azithromycin, clarithromycin and roxithromycin in plasma and tissue – are there significant differences? *Wiener Klinische Wochenschrift*. 2004; 11-12a: 18-24.
- 12) Graninger W, **Zeitlinger M**. Clinical applications of levofloxacin for severe infections. *Chemotherapy*. 2004;50 Suppl 1:16-21.
- 13) Brunner M, Langer O, Dobrozemsky G, Muller U, **Zeitlinger M**, Mitterhauser M, Wadsak W, Dudczak R, Kletter K, Muller M. [¹⁸F]Ciprofloxacin, a new positron emission tomography tracer for non invasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. *Antimicrob Agents Chemother*. 2004 Oct;48(10):3850-7.
- 14) **Zeitlinger M**, Sauermann R, Traunmuller F, Georgopoulos A, Muller M, Joukhadar C. Impact of plasma protein binding on antimicrobial activity using time-killing curves. *J Antimicrob Chemother*. 2004 Nov;54(5):876-80.
- 15) Gattlinger R, Urbauer E, Traunmuller F, **Zeitlinger M**, Dehghanyar P, Zeleny P, Graninger W, Muller M, Joukhadar C. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. *Antimicrob Agents Chemother*. 2004 Dec;48(12):4650-3.

- 16) Sauermann R, Delle-Karth G, Marsik C, Steiner I, Mayer BX, **Zeitlinger M**, Georgopoulos A, Muller M, Joukhadar C. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. *Antimicrob Agents Chemother*. 2005 Feb;49(2):650-5.
- 17) Langer O, Brunner M, **Zeitlinger M**, Ziegler S, Muller U, Dobrozemsky G, Lackner E, Joukhadar C, Mitterhauser M, Wadsak W, Minar E, Dudczak R, Kletter K, Muller M. In vitro and in vivo evaluation of [(18)F]ciprofloxacin for the imaging of bacterial infections with PET. *Eur J Nucl Med Mol Imaging*. 2005 Feb;32(2):143-50.
- 18) Dehghanyar P, Bürger C, **Zeitlinger M**, Islinger F, Kovar F, Muller M, Kloft C, Joukhadar C. Penetration of linezolid into soft tissues after single and multiple doses to healthy volunteers. *Antimicrob Agents Chemother*. 2005 Jun;49(6):2367-71.
- 19) Traunmuller F, Gatringer R, **Zeitlinger M**, Graninger W, Muller M, Joukhadar C. Determination of telithromycin in human plasma and microdialysates by high-performance liquid chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2005 Aug 5;822(1-2):133-6.
- 20) Traunmuller F, Haslinger I, Lagler H, Wolfgang G, **Zeitlinger M**, Abdel Salam HA. Influence of the washing buffer composition on the sensitivity of an enzyme-linked immunosorbent assay using mycobacterial glycolipids as capture antigens. *J Immunoassay Immunochem*. 2005;26(3):179-88.
- 21) **Zeitlinger M**, Schmidinger M, Zielinski CC, Chott A, Raderer M. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab. *Leuk Lymphoma*. 2005 May;46(5):771-4.
- 22) **Zeitlinger M**, Erovic B, Sauermann R, Georgopoulos A, Muller M, Joukhadar C. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. *J Antimicrob Chemother*. 2005 Oct;56(4):703-8.
- 23) Langer O, Karch R, Muller U, Dobrozemsky G, Abraham A, **Zeitlinger M**, Lackner E, Joukhadar C, Dudczak R, Kletter K, Muller M, Brunner M. Combined PET and Microdialysis for In Vivo Assessment of Intracellular Drug Pharmacokinetics in Humans. *J Nucl Med*. 2005 Nov;46(11):1835-41.
- 24) **Zeitlinger M**, Muller M, Joukhadar C. Lung microdialysis – a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract. *AAPS J*. 2005 Oct 22;7(3):E600-8.
- 25) Traunmuller F, Steiner I, **Zeitlinger M**, Joukhadar C. Development of a high-performance liquid chromatography method for the determination of caspofungin with amperometric detection and its application to in vitro microdialysis experiments. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2006 Nov 7;843(2):142-6.
- 26) Gatringer R, Meyer B, Heinz G, Guttmann C, **Zeitlinger M**, Joukhadar C, Dittrich P, Thalhammer F. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. *J Antimicrob Chemother*. 2006 Aug;58(2):367-71.
- 27) **Zeitlinger M**, Marsik C, Steiner I, Sauermann R, Seir K, Jilma B, Wagner O, Joukhadar C. Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. *J Antimicrob Chemother*. 2007 Feb;59(2):219-23.
- 28) **Zeitlinger MA**, Traunmuller F, Abraham A, Muller MR, Erdogan Z, Muller M, Joukhadar C. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. *Int J Antimicrob Agents*. 2007 Jan;29(1):44-50.
- 29) Zeitlinger B, **Zeitlinger M**, Leitner I, Muller M, Joukhadar C. A clinical scoring system for the prediction of target site penetration of antimicrobials in septic patients. *Clin Pharmacokinet*. 2007;46(1):75-83.

- 30) Sauermann R, Marsik C, Steiner I, Seir K, Civtko T, **Zeitlinger M**, Wagner O, Joukhadar C. The immunomodulatory effects of fosfomycin in experimental human endotoxemia. *Antimicrob Agents Chemother*. 2007 May;51(5):1879-81.
- 31) Traunmüller F, **Zeitlinger M**, Zeleny P, Müller M, Joukhadar C. Single- and multiple-dose pharmacokinetics of oral clarithromycin in soft tissues determined by microdialysis. *Antimicrob Agents Chemother*. 2007 Sep;51(9):3185-9.
- 32) **Zeitlinger M**, Sauermann R, Fille M, Hausdorfer J, Leitner I, Müller M. Plasma protein binding of fluoroquinolones affects antimicrobial activity. *J Antimicrob Chemother*. 2008 Mar;61(3):561-7.
- 33) Hutschala D, Kinstner C, Skhirtladze K, Mayer-Helm BX, **Zeitlinger M**, Wisser W, Müller M, Tschernko E. The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. *Intensive Care Med*. 2008 Oct;34(10):1827-34.
- 34) Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. Collaborators: Marth E, Konior R, Sonnenburg F, Birthistle K, Dvorak T, Geyer S, Kraft M, Leitgeb MC, Maritsch F, Phillipson L, Robotka E, Abraham A, Bauer M, Brunner M, Cornea A, Drucker C, Erdogan Z, Griss J, Heinisch B, Kovar F, Lackner E, Lambers C, Langer O, Leitner I, Marsik C, Poepl W, Popovic M, Sauermann R, Schaberl R, Sodeck G, Thallinger C, Traunmüller F, Wagner C, **Zeitlinger M**, Chua SK, Chuin S, Fong R, Foo AS, Koh AG, Lim PK, Yap SY, Yew LH, Goh JW, Hsu LY, Loke CW, Ng JY, Toh EL, Weatherill P, Zhou YP. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. *N Engl J Med*. 2008 Jun 12;358(24):2573-84.
- 35) Sauermann R, Schwameis R, Fille M, Camuz Ligios ML, **Zeitlinger M**. Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro. *J Antimicrob Chemother*. 2008 Nov;62(5):1057-60.
- 36) **Zeitlinger M**, Wagner CC, Heinisch B. Ketolides - the modern relatives of macrolides: the pharmacokinetic perspective. *Clin Pharmacokinet*. 2009;48(1):23-38.
- 37) Beer J, Wagner CC, **Zeitlinger M**. Protein Binding of Antimicrobials: Methods for Quantification and for Investigation of its Impact on Bacterial Killing. *AAPS J*. 2009 Mar;11(1):1-12.
- 38) Wagner CW, Biollaz B, **Zeitlinger M**, Buclin T. „Iatrogenic cascade“: doing harm by treating harm? *Wien Med Wochenschr*. 2009;159(1-2):53-57.
- 39) Wagner CC, Steiner I, **Zeitlinger M**. Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption. *Int J Clin Pharmacol Ther*. 2009 Mar;47(3):178-86.
- 40) Sauermann R, Schwameis R, Fille M, Camuz Ligios ML, **Zeitlinger M**. Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. *J Antimicrob Chemother*. 2009 Jul 21. *J Antimicrob Chemother*. 2009 Oct;64(4):821-3.
- 41) Bauer M, Karch R, Neumann F, Abraham A, Wagner CC, Kletter K, Müller M, **Zeitlinger M**, Langer O. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. *Eur J Clin Pharmacol*. 2009 Sep;65(9):941-6.
- 42) Ehrlich HJ, Müller M, Fritsch S, **Zeitlinger M**, Berezuk G, Löw-Baselli A, van der Velden MV, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P. A Cell Culture (Vero)-Derived H5N1 Whole-Virus Vaccine Induces Cross-Reactive Memory Responses. *J Infect Dis*. 2009 Oct 1;200(7):1113-8.
- 43) Capan M, Keltner S, Thalhammer F, Winkler S, Jäger W, **Zeitlinger M**, Ramharter M. Intra-cystic drug concentration of albendazole sulphoxide in patients with *Echinococcus granulosus* cysts. *Am J Trop Med Hyg*. 2009 Oct;81(4):712-3.
- 44) Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, Kletter K, Löscher W, Müller M, **Zeitlinger M**, Langer O. A Pilot Study to Assess the Efficacy of Tariquidar to

- Inhibit P-glycoprotein at the Human Blood-Brain Barrier with (R)-11C-Verapamil and PET. *J Nucl Med*. 2009 Dec;50(12):1954-61.
- 45) Bauer M, Karch R, Neumann F, Wagner CC, Kletter K, Müller M, Löscher W, **Zeitlinger M**, Langer O. Assessment of regional differences in tariquidar induced P-glycoprotein modulation at the human blood-brain barrier. *J Cereb Blood Flow Metab*. 2010 Mar;30(3):510-5.
 - 46) Latzke D, Marhofer P, **Zeitlinger M**, Machata A, Neumann F, Lackner E, Kettner SC. Minimal local anaesthetic volumes for sciatic nerve block: evaluation of ED99 in volunteers. *Br J Anaesth*. 2010 Feb;104(2):239-44.
 - 47) Lambers C, Burian B, Binder P, Ankersmit HJ, Wagner C, Müller M, **Zeitlinger M**. Early immunomodulatory effects of linezolid in a human whole blood endotoxin model. *Int J Clin Pharmacol Ther*. 2010 Jul;48(7):419-24.
 - 48) Krasniqi SH, **Zeitlinger M**, Bauer S. Comparison between the Immunoassay and High Performance Liquid Chromatography for Therapeutic Monitoring of Carbamazepine and Phenytoine. *Biochemia Medica*. Volume 20, October (https://doi.org/10.11613/BM.2010.044)
 - 49) Burian A, Wagner C, Stanek J, Manafi M, Böhmendorfer M, Jäger W, **Zeitlinger M**. Plasma protein binding may reduce antimicrobial activity by preventing intra-bacterial uptake of antibiotics – example clindamycin. *J Antimicrob Chemother*. 2011 Jan;66(1):134-7.
 - 50) Crowe BA, Brühl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, **Zeitlinger M**, Müller M, Ehrlich H, Barrett PN. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. *Vaccine*. 2010 Dec 16;29(2):166-73.
 - 51) Wagner CC, Simpson M, **Zeitlinger M**, Bauer M, Karch R, Abraham A, Feurstein T, Schütz M, Kletter K, Müller M, Lappin G, Langer O. A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil. *Clin Pharmacokinet*. 2011 Feb 1;50(2):111-20.
 - 52) Erdogan-Yildirim Z, Burian A, Manafi M, **Zeitlinger M**. Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. *Res Microbiol*. 2011 Apr;162(3):249-52.
 - 53) Leitner I, Nemeth J, Feurstein T, Abraham A, Matzneller P, Lagler H, Erker T, Langer O, **Zeitlinger M**. The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. *J Antimicrob Chemother*. 2011 Apr;66(4):834-9.
 - 54) **Zeitlinger MA**, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. Protein binding - do we ever learn? *Antimicrob Agents Chemother*. 2011 Jul;55(7):3067-74.
 - 55) Matzneller P, Manafi M, **Zeitlinger M**. Antimicrobial effect of statins: organic solvents might falsify microbiological testing results. *Int J Clin Pharmacol Ther*. 2011 Nov;49(11):666-71.
 - 56) Latzke D, Marhofer P, Kettner SC, Koppatz K, Turnheim K, Lackner E, Sauermann R, Müller M, **Zeitlinger M**. Pharmacokinetics of the local anesthetic ropivacaine after transversus abdominis plane block in healthy volunteers. *Eur J Clin Pharmacol*. 2012 Apr;68(4):419-25.
 - 57) Bauer M, **Zeitlinger M**, Karch R, Matzneller P, Stanek J, Jäger W, Böhmendorfer M, Wadsak W, Mitterhauser M, Bankstahl JP, Löscher W, Koepp M, Kuntner C, Müller M, Langer O. Pgp-Mediated Interaction Between (R)-[(11)C]Verapamil and Tariquidar at the Human Blood-Brain Barrier: A Comparison With Rat Data. *Clin Pharmacol Ther*. 2012 Feb;91(2):227-33.

- 58) Krasniqi S, Matzneller P, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, **Zeitlinger M**. Blood, tissue and intracellular concentrations of Erythromycin and its metabolite anhydro-erythromycin during and after end of therapy. *Antimicrob Agents Chemother*. 2012 Feb;56(2):1059-64.
- 59) Burian B, **Zeitlinger M**, Donath O, Reznicek G, Sauermann R. Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers. *Antimicrob Agents Chemother*. 2012 Jan;56(1):532-5.
- 60) Schwameis R, Fille M, Manafi M, **Zeitlinger M**, Sauermann R. Enhanced activity of linezolid against *Staphylococcus aureus* in cerebrospinal fluid. *Res Microbiol*. 2012 Apr;163(3):157-60.
- 61) Poepl W, **Zeitlinger M**, Donath O, Wurm G, Müller M, Botha F, Illievich UM, Burgmann H. Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury. *Int J Antimicrob Agents*. 2012 Apr;39(4):343-5.
- 62) Matzneller P, Burian A, Martin W, Annoni O, Lauro V, Tacchi R, Brunner M, **Zeitlinger M**. A Randomised, Two-Period, Cross-Over, Open-Label Study to Evaluate the Pharmacokinetic Profiles of Single Doses of Two Different Flurbiprofen 8.75-mg Lozenges in Healthy Volunteers. *Pharmacology*. 2012 Mar 20;89(3-4):188-191.
- 63) Sauermann R, Feurstein T, Karch R, Kjellsson MC, Jäger W, Böhmendorfer M, Püspök A, Langenberger H, Wild T, Winkler S, **Zeitlinger M**. Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus. *Eur J Clin Pharmacol*. 2012 Oct;68(10):1419-23.
- 64) Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, **Zeitlinger M**, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. *Vaccine*. 2012 Jun 22;30(30):4543-51.
- 65) Jäger U, Fridrik M, **Zeitlinger M**, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabcs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. *Haematologica*. 2012 Sep;97(9):1431-8.
- 66) Tobudic S, Matzneller P, Stoiser B, Wenisch JM, **Zeitlinger M**, Vychytil A, Jaeger W, Boehmendorfer M, Reznicek G, Burgmann H. Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. *Antimicrob Agents Chemother*. 2012 Jul;56(7):3992-5.
- 67) **Zeitlinger M**, Rusca A, Oraha AZ, Gugliotta B, Müller M, Ducharme MP. Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration. *Int J Clin Pharmacol Ther*. 2012 Jun;50(6):383-90.
- 68) Duchateau GS, Cochrane B, Windebank S, Herudzinska J, Sanghera D, Burian A, Muller M, **Zeitlinger M**, Lappin G. Absolute Oral Bioavailability and Metabolic Turnover of β -sitosterol in Healthy Subjects. *Drug Metab Dispos*. 2012 Oct;40(10):2026-30.
- 69) Sauermann R, Karch R, Kjellsson MC, Feurstein T, Püspök A, Langenberger H, Böhmendorfer M, Jäger W, **Zeitlinger M**. Good Penetration of Moxifloxacin into Human Abscesses. *Pharmacology*. 2012 Aug 3;90(3-4):146-150.
- 70) van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, **Zeitlinger M**, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming. *Vaccine*. 2012 Sep 21;30(43):6127-35.
- 71) Schwameis R, **Zeitlinger M**. Methods to measure target site penetration of antibiotics in critically ill patients. *Curr Clin Pharmacol*. 2013 Feb 1;8(1):46-58. Review.

- 72)Burian A, Erdogan Z, Jandrisits C, **Zeitlinger M**. Impact of pH on Activity of Trimethoprim, Fosfomycin, Amikacin, Colistin and Ertapenem in Human Urine. *Pharmacology*. 2012;90(5-6):281-7.
- 73)Simmel F, Kirbs C, Erdogan Z, Lackner E, **Zeitlinger M**, Kloft C. Pilot Investigation on Long-Term Subcutaneous Microdialysis: Proof of Principle in Humans. *AAPS J*. 2013 Jan;15(1):95-103.
- 74)Bauer M, **Zeitlinger M**, Todorut D, Böhmendorfer M, Müller M, Langer O, Jäger W. Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects. *Pharmacology*. 2012 Nov 7;91(1-2):12-19.
- 75)Marhofer D, Kettner SC, Marhofer P, Pils S, Weber M, **Zeitlinger M**. Dexmedetomidine as an adjuvant to ropivacaine prolongs peripheral nerve block: a volunteer study. *Br J Anaesth*. 2013 Mar;110(3):438-42.
- 76)Sauermann R, Burian B, Burian A, Jäger W, Höferl M, Stella A, Theurer S, Riedl M, **Zeitlinger M**. Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections. *J Antimicrob Chemother*. 2013 Apr;68(4):895-9.
- 77)Matzneller P, Krasniqi S, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, **Zeitlinger M**. Blood, tissue and intracellular concentrations of Azithromycin and after end of therapy. *Antimicrob Agents Chemother*. 2013 Apr;57(4):1736-42.
- 78)Marhofer D, Marhofer P, Kettner SC, Fleischmann E, Prayer D, Schernthaner M, Lackner E, Willschke H, Schwetz P, **Zeitlinger M**. Magnetic Resonance Imaging Analysis of the Spread of Local Anesthetic Solution after Ultrasound-guided Lateral Thoracic Paravertebral Blockade: A Volunteer Study. *Anesthesiology*. 2013 May;118(5):1106-12.
- 79)Andreas M, **Zeitlinger M**, Hoferl M, Jaeger W, Zimpfer D, Hiesmayr JM, Laufer G, Hutschala D. Internal mammary artery harvesting influences antibiotic penetration into presternal tissue. *Ann Thorac Surg*. 2013 Apr;95(4):1323-30.
- 80)Mitteregger D, Wolfgang B, Nehr M, Kundi M, **Zeitlinger M**, Makristathis A, Hirschl AM. Neutralization of antimicrobial substances in new BacT/ALERT(R) FA and FN Plus blood culture bottles. *J Clin Microbiol*. 2013 May;51(5):1534-40.
- 81)Burian A, Frangione V, Rovati S, Mautone G, Leuratti C, Vaccani A, Crevenna R, Keilani M, Burian B, Brunner M, **Zeitlinger M**. An exploratory microdialysis study investigating the effect of repeated application of a diclofenac epolamine medicated plaster on prostaglandin concentrations in skeletal muscle after standardized physical exercise. *Br J Clin Pharmacol*. 2013 Dec;76(6):880-7.
- 82)Hutschala D, Skhirtladze K, Kinstner C, **Zeitlinger M**, Wissner W, Jaeger W, Hoferl M, Müller M, Tschernko E. Effect of cardiopulmonary bypass on regional antibiotic penetration into lung tissue. *Antimicrob Agents Chemother*. 2013 Jul;57(7):2996-3002.
- 83)Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, **Zeitlinger M**, Müller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. *Lancet Infect Dis*. 2013 Aug;13(8):680-9.
- 84)Marhofer D, Marhofer P, Triffterer L, Leonhardt M, Weber M, **Zeitlinger M**. Dislocation rates of perineural catheters: a volunteer study. *Br J Anaesth*. 2013 Nov;111(5):800-6.
- 85)Bauer M, Karch R, **Zeitlinger M**, Stanek J, Philippe C, Wadsak W, Mitterhauser M, Jäger W, Haslacher H, Müller M, Langer O. Interaction of 11C-Tariquidar and 11C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood-Brain Barrier. *J Nucl Med*. 2013 Aug;54(8):1181-7.
- 86)Schwameis R, Erdogan-Yildirim Z, Manafi M, **Zeitlinger MA**, Strommer S, Sauermann R. Effect of pulmonary surfactant on antimicrobial activity in-vitro. *Antimicrob Agents Chemother*. 2013 Oct;57(10):5151-4.

- 87) Andreas M, **Zeitlinger M**, Hoefler M, Jaeger W, Zimpfer D, Hiesmayr JM, Laufer G, Hutschala D. Reply. *Ann Thorac Surg*. 2013 Oct;96(4):1528-9.
- 88) Schwameis R, Eder S, Pietschmann H, Fischer B, Mascher H, Tzotzos S, Fischer H, Lucas R, **Zeitlinger M**, Hermann R. A FIM Study to Assess Safety and Exposure of Inhaled Single Doses of AP301-A Specific ENaC Channel Activator for the Treatment of Acute Lung Injury. *J Clin Pharmacol*. 2014 Mar;54(3):341-50.
- 89) Poepl W, Lingscheid T, Bernitzky D, Donath O, Reznicek G, **Zeitlinger M**, Burgmann H. Assessing Pharmacokinetics of Different Doses of Fosfomycin in Laboratory Rats Enables Adequate Exposure for Pharmacodynamic Models. *Pharmacology*. 2014 Feb 5;93(1-2):65-68.
- 90) Marhofer D, Karmakar MK, Marhofer P, Kettner SC, Weber M, **Zeitlinger M**. Does circumferential spread of local anaesthetic improve the success of peripheral nerve block? *Br J Anaesth*. 2014 Jul;113(1):177-85.
- 91) Eslam RB, Burian A, Vila G, Sauermann R, Hammer A, Frenzel D, Minichmayr IK, Kloft C, Matzneller P, Oesterreicher Z, **Zeitlinger M**. Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection. *J Clin Pharmacol*. 2014 Sep;54(9):1058-62.
- 92) Wulkersdorfer B, Wanek T, Bauer M, **Zeitlinger M**, Müller M, Langer O. Using Positron Emission Tomography to Study Transporter-Mediated Drug-Drug Interactions in Tissues. *Clin Pharmacol Ther*. 2014 Aug;96(2):206-13.
- 93) Lagler H, **Zeitlinger M**. [Tissue penetration of antibiotics : Does the treatment reach the target site?]. *Med Klin Intensivmed Notfmed*. 2014 Apr;109(3):175-81.
- 94) van der Velden MV, Geisberger A, Dvorak T, Portsmouth D, Fritz R, Crowe BA, Herr W, Distler E, Wagner EM, **Zeitlinger M**, Sauermann R, Stephan C, Ehrlich HJ, Barrett PN, Aichinger G. Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients. *Clin Vaccine Immunol*. 2014 Jun;21(6):867-76.
- 95) Cvikl B, Klimscha J, Holly M, **Zeitlinger M**, Gruber R, Moritz A. Removal of fractured endodontic instruments using an Nd:YAG laser. *Quintessence Int*. 2014;45(7):569-75.
- 96) Zheng S, Matzneller P, **Zeitlinger M**, Schmidt S. Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. *Antimicrob Agents Chemother*. 2014 Nov;58(11):6675-84.
- 97) Wressnigg N, Barrett PN, Pöllabauer EM, O'Rourke M, Portsmouth D, Schwendinger MG, Crowe BA, Livey I, Dvorak T, Schmitt B, **Zeitlinger M**, Kollaritsch H, Esen M, Kremsner PG, Jelinek T, Aschoff R, Weisser R, Naudts IF, Aichinger G. A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with *Borrelia burgdorferi* Sensu Lato. *Clin Vaccine Immunol*. 2014 Nov;21(11):1490-9.
- 98) Bauer M, Karch R, **Zeitlinger M**, Liu J, Koepp MJ, Asselin MC, Sisodiya SM, Hainfellner JA, Wadsak W, Mitterhauser M, Müller M, Pataria E, Langer O. In vivo P-glycoprotein function before and after epilepsy surgery. *Neurology*. 2014 Oct 7;83(15):1326-31.
- 99) Matzneller P, Gobin P, Lackner E, **Zeitlinger M**. Feasibility of microdialysis for determination of protein binding and target site pharmacokinetics of colistin in vivo. *J Clin Pharmacol*. 2015 Apr;55(4):431-7.
- 100) Bauer M, Schwameis R, Scherzer T, Lang-Zwosta I, Nishino K, **Zeitlinger M**. A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. *J Dermatolog Treat*. 2014 Nov 26:1-22.
- 101) Andreas M, **Zeitlinger M**, Wisser W, Jaeger W, Maier-Salamon A, Thalhammer F, Kocher A, Hiesmayr JM, Laufer G, Hutschala D. Cefazolin and linezolid penetration

- into sternal cancellous bone during coronary artery bypass grafting. *Eur J Cardiothorac Surg*. 2015 Nov;48(5):758-64.
- 102) Keplinger M, Marhofer P, Marhofer D, Schroegendorfer K, Haslik W, **Zeitlinger M**, Mayer CV, Kettner SC. Effective local anaesthetic volumes for sciatic nerve blockade: a clinical evaluation of the ED₉₉. *Anaesthesia*. 2015 May;70(5):585-90.
 - 103) Bauer M, Karch R, **Zeitlinger M**, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M, Müller M, Langer O. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[(11)C]verapamil PET study. *J Cereb Blood Flow Metab*. 2015 May;35(5):743-6.
 - 104) Keplinger M, Marhofer P, Kettner SC, Marhofer D, Kimberger O, **Zeitlinger M**. A pharmacodynamic evaluation of dexmedetomidine as an additive drug to ropivacaine for peripheral nerve blockade: A randomised, triple-blind, controlled study in volunteers. *Eur J Anaesthesiol*. 2015 Nov;32(11):790-6.
 - 105) Schoergenhofer C, Schwameis M, Brunner M, **Zeitlinger M**, Winkler F, Jilma B, Brunner-Ziegler S. Assessing the influence of diurnal variations and selective Xa inhibition on whole blood aggregometry. *Scand J Clin Lab Invest*. 2015 Oct;75(6):531-6.
 - 106) Matzneller P, Strommer S, Österreicher Z, Mitteregger D, **Zeitlinger M**. Target site antimicrobial activity of colistin might be misestimated if tested in conventional growth media. *Eur J Clin Microbiol Infect Dis*. 2015 Oct;34(10):1989-94.
 - 107) Wulkersdorfer B, **Zeitlinger M**, Schmid M. Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. *Clin Pharmacokinet*. 2016 Jan;55(1):47-77.
 - 108) Crevenna R, Burian A, Oesterreicher Z, Lackner E, Jäger W, Reznicek G, Keilani M, **Zeitlinger M**. Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. *Eur J Clin Pharmacol*. 2015 Nov;71(11):1359-64.
 - 109) Kussmann M, Schuster L, **Zeitlinger M**, Pichler P, Reznicek G, Wiesholzer M, Burgmann H, Poepl W. The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against *Enterococcus faecalis*. *Eur J Clin Microbiol Infect Dis*. 2015 Nov;34(11):2257-63.
 - 110) Hosmann A, Schober A, Gruber A, Sterz F, Testori C, Warenits A, Weihs W, Högl S, Scherer T, Janata A, Laggner A, **Zeitlinger M**. Cerebral and Peripheral Metabolism to Predict Successful Reperfusion After Cardiac Arrest in Rats: A Microdialysis Study. *Neurocrit Care*. 2016 Apr;24(2):283-93.
 - 111) **Zeitlinger M**, Schwameis R, Burian A, Burian B, Matzneller P, Müller M, Wicha WW, Strickmann DB, Prince W. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. *J Antimicrob Chemother*. 2016 Apr;71(4):1022-6.
 - 112) Schrottmaier WC, Kral JB, **Zeitlinger M**, Salzmann M, Jilma B, Assinger A. Platelet activation at the onset of human endotoxemia is undetectable in vivo. *Platelets*. 2016 Jan 14:1-5.
 - 113) Matzneller P, Burian A, **Zeitlinger M**, Sauermann R. Understanding the Activity of Antibiotics in Cerebrospinal Fluid in vitro. *Pharmacology*. 2016;97(5-6):233-44.
 - 114) Wiesholzer M, Pichler P, Reznicek G, Wimmer M, Kussmann M, Balcke P, Burgmann H, **Zeitlinger M**, Poepl W. An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis. *Antimicrob Agents Chemother*. 2016 Apr 22;60(5):2790-7.
 - 115) Bauer M, Römermann K, Karch R, Wulkersdorfer B, Stanek J, Philippe C, Maier-Salamon A, Haslacher H, Jungbauer C, Wadsak W, Jäger W, Löscher W, Hacker M, **Zeitlinger M**, Langer O. A pilot PET study to assess the functional interplay between

- ABCB1 and ABCG2 at the human blood-brain barrier. *Clin Pharmacol Ther.* 2016 Aug;100(2):131-41.
- 116) Matzneller P, Lackner E, Lagler H, Wulkersdorfer B, Österreicher Z, **Zeitlinger M**. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. *Antimicrob Agents Chemother.* 2016 May 23;60(6):3617-25.
 - 117) Bauer M, Blaickner M, Philippe C, Wadsak W, Hacker M, **Zeitlinger M**, Langer O. Whole-body Distribution and Radiation Dosimetry of ¹¹C-Elacridar and ¹¹C-Tarividar in Humans. *J Nucl Med.* 2016 Aug;57(8):1265-8.
 - 118) Klaus R, Jin C, Maier-Salamon A, Jäger W, Knopf C, **Zeitlinger M**, Richter-Müksch S, Schmidl D, Schmetterer L, Garhöfer G. An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. *J Ocul Pharmacol Ther.* 2016 Jul-Aug;32(6):390-5.
 - 119) Schwameis R, Pils S, Weber M, Hagmann M, **Zeitlinger M**, Sauermann R. Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. *Pharmacology.* 2016;98(1-2):93-8.
 - 120) Schober A, Warenits AM, Testori C, Weihs W, Hosmann A, Högler S, Sterz F, Janata A, Scherer T, Magnet IA, Ettl F, Laggner AN, Herkner H, **Zeitlinger M**. Microdialysis Assessment of Cerebral Perfusion during Cardiac Arrest, Extracorporeal Life Support and Cardiopulmonary Resuscitation in Rats - A Pilot Trial. *PLoS One.* 2016 May 13;11(5):e0155303.
 - 121) Keplinger M, Marhofer P, Klug W, Reiter B, Stimpfl T, Kettner SC, Korf L, **Zeitlinger M**, Marhofer D, Triffterer L. Feasibility and pharmacokinetics of caudal blockade in children and adolescents with 30-50 kg of body weight. *Paediatr Anaesth.* 2016 Nov;26(11):1053-1059.
 - 122) Thaler B, Hohensinner PJ, Krychtiuk KA, Matzneller P, Koller L, Brekalo M, Maurer G, Huber K, **Zeitlinger M**, Jilma B, Wojta J, Speidl WS. Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humans. *Sci Rep.* 2016 Jul 22;6:30162.
 - 123) Matzneller P, Österreicher Z, Reiter B, Lackner E, Stimpfl T, **Zeitlinger M**. Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study. *J Antimicrob Chemother.* 2016 Nov;71(11):3179-3184.
 - 124) Wiesholzer M, Winter A, Kussmann M, **Zeitlinger M**, Pichler P, Burgmann H, Reznicek G, Poepl W. Compatibility of Meropenem with different commercial peritoneal dialysis solutions. *Perit Dial Int.* 2017 1-2;37(1):51-55.
 - 125) Kussmann M, Schuster L, Wrenger S, Pichler P, Reznicek G, Burgmann H, Poepl W, **Zeitlinger M**, Wiesholzer M. Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli. *Perit Dial Int.* 2016 11-12;36(6):662-668.
 - 126) Bauer M, Karch R, Tournier N, Cisternino S, Wadsak W, Hacker M, Marhofer P, **Zeitlinger M**, Langer O. Assessment of P-glycoprotein Transport Activity at the Human Blood-Retinal Barrier with (R)-¹¹C-verapamil PET. *J Nucl Med.* 2017 Apr;58(4):678-681.
 - 127) Minichmayr IK, Schaeflein A, Kuti JL, **Zeitlinger M**, Kloft C. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. *Clin Pharmacokinet.* 2017 Jun;56(6):617-633.
 - 128) Matzneller P, Strommer S, Drucker C, Petroczi K, Schörghofer C, Lackner E, Jilma B, **Zeitlinger M**. Colistin reduces LPS-triggered inflammation in a human sepsis model in vivo: A randomized controlled trial. *Clin Pharmacol Ther.* 2017 Jun;101(6):773-781.

- 129) Scarpignato C, Dolak W, Lanås A, Matzneller P, Renzulli C, Grimaldi M, **Zeitlinger M**, Bjarnason I. Rifaximin Reduces Number and Severity of Intestinal Lesions Associated With use of Non-steroidal Anti-inflammatory Drugs in Humans. *Gastroenterology*. 2017 Apr;152(5):980-982.e3.
- 130) Matsuda A, Karch R, Bauer M, Traxl A, **Zeitlinger M**, Langer O. A Prediction Method for P-glycoprotein-Mediated Drug-Drug Interactions at the Human Blood-Brain Barrier From Blood Concentration-Time Profiles, Validated With PET Data. *J Pharm Sci*. 2017 Sep;106(9):2780-2786.
- 131) Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jäger W, Stanek J, Wadsak W, Hacker M, **Zeitlinger M**, Langer O. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[(11) C]verapamil in elderly vs. young subjects. *Br J Clin Pharmacol*. 2017 Sep;83(9):1991-1999.
- 132) Matt U, Selchow P, Dal Molin M, Strommer S, Sharif O, Schilcher K, Andreoni F, Stenzinger A, Zinkernagel AS, **Zeitlinger M**, Sander P, Nemeth J. Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux. *Int J Antimicrob Agents*. 2017 Jul;50(1):55-62.
- 133) Wulkersdorfer B, Jaros D, Eberl S, Poschner S, Jäger W, Cosentini E, **Zeitlinger M**, Schwameis R. Human Bile Reduces Antimicrobial Activity of Selected Antibiotics Against *Enterococcus faecalis* and *Escherichia coli* in vitro. *Antimicrob Agents Chemother*. 2017 Jul 25;61(8).
- 134) Kussmann M, Baumann A, Hauer S, Pichler P, **Zeitlinger M**, Wiesholzer M, Burgmann H, Poepl W, Reznicek G. Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. *Eur J Clin Microbiol Infect Dis*. 2017 Nov;36(11):2237-2242.
- 135) Schwameis R, Syré S, Marhofer D, Appelt A, Burau D, Sarahrudi K, Kloft C, **Zeitlinger M**. Pharmacokinetics of Cefuroxime in Synovial Fluid. *Antimicrob Agents Chemother*. 2017 Sep 22;61(10).
- 136) Schoergenhofer C, Matzneller P, Mußbacher M, Schmid JA, Jilma-Stohlawetz P, **Zeitlinger M**, Jilma B. Colistin dampens fibrinolysis and endothelial activation during endotoxaemia. A randomised, double blind trial. *Thromb Haemost*. 2017 Aug 30;117(9):1714-1721.
- 137) Ernstbrunner M, Kabon B, Zotti O, **Zeitlinger M**, Berner C, Hinterholzer G, Säemann M, Frommlet F, Fleischmann E, Hecking M. Intravenous Fluid Challenge Decreases Intracellular Volume: A Bioimpedance Spectroscopy-Based Crossover Study in Healthy Volunteers. *Sci Rep*. 2017 Aug 29;7(1):9644.
- 138) Oesterreicher Z, Minichmayr I, Sauermann R, Marhofer D, Lackner E, Jäger W, Maier-Salamon A, Schwameis R, Kloft C, **Zeitlinger M**. Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens. *Eur J Clin Pharmacol*. 2017 Dec;73(12):1609-1613.
- 139) Bauer M, Matsuda, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM, Poschner S, Jäger W, Patik I, Bakos É, Szakács G, Wadsak W, Hacker M, **Zeitlinger M**, Langer O. Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. *Clin Pharmacol Ther*. 2018 Jul;104(1):139-147.
- 140) Staufer K, Dengler M, Huber H, Marculescu R, Stauber R, Lackner C, Dienes HP, Kivaranovic D, Schachner C, **Zeitlinger M**, Wulkersdorfer B, Rauch P, Prager G, Trauner M, Mikulits W. The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. *Cell Death Dis*. 2017 Oct 26;8(10):e3135.
- 141) Schwameis R, Syré S, Sarahrudi K, Appelt A, Marhofer D, Burau D, Kloft C, **Zeitlinger M**. Penetration of linezolid into synovial fluid and muscle tissue after elective arthroscopy. *J Antimicrob Chemother*. 2017 Oct 1;72(10):2817-2822.

- 142) Dorn C, Nowak H, Weidemann C, Martini S, **Zeitlinger M**, Adamzik M, Kees F. Decreased protein binding of moxifloxacin in patients with sepsis? *GMS Infect Dis.* 2017 Feb 3;5:Doc03.
- 143) Hosmann A, Ritscher LC, Burgmann H, Oesterreicher Z, Jäger W, Poschner S, Knosp E, Reinprecht A, Gruber A, **Zeitlinger M**. Concentrations of cefuroxime in brain tissue of neurointensive care patients. *Antimicrob Agents Chemother.* 2018 Jan 25;62(2):e02164-17.
- 144) Al Jalali V, **Zeitlinger M**. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides. *Clin Pharmacokinet.* 2018 Jul;57(7):797-816.
- 145) Vossen MG, Ehmann L, Pferschy S, Maier-Salamon A, Haidinger M, Weiser C, Wenisch JM, Saria K, Kajahn C, Jilch S, Lemmerer R, Bécède M, **Zeitlinger M**, Kloft C, Jäger W, Thalhammer F. Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy. *Antimicrob Agents Chemother.* 2018 Apr 26;62(5):e02430-17.
- 146) Kussmann M, Hauer S, Pichler P, Reznicek G, Burgmann H, Poepl W, **Zeitlinger M**, Wiesholzer M. Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against *Escherichia coli*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis.* 2018 Jun;37(6):1091-1098.
- 147) Keplinger M, Marhofer P, Moriggl B, **Zeitlinger M**, Muehleder-Matterey S, Marhofer D. Cutaneous innervation of the hand: clinical testing in volunteers shows high intra- and inter-individual variability. *Br J Anaesth.* 2018 Apr;120(4):836-845.
- 148) **Zeitlinger M**. Extended infusion-putting the benefit into context. *Lancet Infect Dis.* 2018 Apr;18(4):380-381.
- 149) Matzneller P, Kussmann M, Eberl S, Maier-Salamon A, Jäger W, Bauer M, Langer O, **Zeitlinger M**, Poepl W. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. *Eur J Drug Metab Pharmacokinet* 2018 Oct;43(5):599-606.
- 150) Weisshaar S, **Zeitlinger M**. Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia? *Drugs.* 2018 Jun;78(8):799-808.
- 151) Andreas M, **Zeitlinger M**, Hutschala D. Comment on: Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass. *J Antimicrob Chemother* 2018 Sep 1;73(9):2587-2588.
- 152) Pal A, Matzneller P, Gautam A, Österreicher Z, Wulkersdorfer B, Reiter B, Stimpfl T, **Zeitlinger M**. Target site pharmacokinetics of doxycycline for rosacea in healthy volunteers is independent of food-effect. *Br J Clin Pharmacol.* 2018 Nov;84(11):2625-2633.
- 153) Oesterreicher Z, Lackner E, Jäger W, Höferl M, **Zeitlinger M**. Lack of dermal penetration of topically applied gentamicin as pharmacokinetic evidence insufficient efficacy. *J Antimicrob Chemother.* 2018 Oct 1;73(10):2823-2829.
- 154) Bauer M, Traxl A, Matsuda A, Karch R, Philippe C, Nics L, Klebermass EM, Wulkersdorfer B, Weber M, Poschner S, Tournier N, Jäger W, Wadsak W, Hacker M, Wanek T, Zeitlinger M, Langer O. Effect of Rifampicin on the Distribution of [(11)C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. *Mol Pharm.* 2018 Oct 1;15(10):4589-4598.
- 155) Bauer M, Karch R, Wulkersdorfer B, Philippe C, Nics L, Klebermass EM, Weber M, Poschner S, Haslacher H, Jäger W, Tournier N, Wadsak W, Hacker M, **Zeitlinger M**, Langer O. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux

- Transport at the Human Blood-Brain Barrier. *J Nucl Med.* 2018 Oct 1;15(10):4589-4598.
- 156) Poepl W, Rainer-Harbach E, Kussmann M, Pichler P, **Zeitlinger M**, Wiesholzer M, Burgmann H, Reznicek G. Compatibility of linezolid with commercial peritoneal dialysis solutions. *Am J Health Syst Pharm.* 2018 Oct 1;75(19):1467-1477.
 - 157) Oesterreicher ZA, Eberl S, Nussbaumer-Proell A, Peilensteiner T, Zeitlinger M. Impact of different pathophysiologic conditions on antimicrobial activity of glycopeptides in vitro. *Clin Microbiol Infect.* 2019 Jun;25(6):759.e1-759.e7.
 - 158) Kratzer A, Schießler S, Matzneller P, Wulkersdorfer B, **Zeitlinger M**, Schlossmann J, Kees F, Dorn C. Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV. *J Pharm Biomed Anal.* 2019 Jan 30;163:34-38.
 - 159) Tournier N, Bauer M, Pichler V, Nics L, Klebermass EM, Bamming K, Matzneller P, Weber M, Karch R, Caille F, Auvity S, Marie S, Jaeger W, Wadsak W, Hacker M, **Zeitlinger M**, Langer O. Impact of P-glycoprotein Function on the Brain Kinetics of the Weak Substrate (11)C-Metoclopramide Assessed with PET Imaging in Humans. *J Nucl Med.* 2019 Jul;60(7):985-991.
 - 160) Nussbaumer-Pröll AK, Knotzer S, Eberl S, Reiter B, Stimpfl T, Jäger W, Poschner S, **Zeitlinger M**. Impact of erythrocytes on bacterial growth and antimicrobial activity of selected antibiotics. *Eur J Clin Microbiol Infect Dis.* 2019 Mar;38(3):485-495.
 - 161) Al Jalali V, Sauermann R, Eberl S, **Zeitlinger M**. In vitro activity of voriconazole and amphotericin B against *Candida albicans*, *Candida krusei*, and *Cryptococcus neoformans* in human cerebrospinal fluid. *Infection.* 2019 Aug;47(4):565-570.
 - 162) Kirbs C, Kluwe F, Drescher F, Lackner E, Matzneller P, Weiss J, **Zeitlinger M**, Kloft C. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. *Eur J Pharm Sci.* 2019 Apr 1;131:218-229.
 - 163) Marhofer P, Columb M, Hopkins PM, Greher M, Marhofer D, Levi Bienzle MR, **Zeitlinger M**. Dexamethasone as an adjuvant for peripheral nerve blockade: a randomised, triple-blinded crossover study in volunteers. *Br J Anaesth.* 2019 Apr;122(4):525-531.
 - 164) Kussmann M, Ferth A, Obermüller M, Pichler P, **Zeitlinger M**, Wiesholzer M, Burgmann H, Poepl W, Reznicek G. Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. *Sci Rep.* 2019 Apr 24;9(1):6512.
 - 165) Hernández Lozano I, Karch R, Bauer M, Blaickner M, Matsuda A, Wulkersdorfer B, Hacker M, **Zeitlinger M**, Langer O. Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. *AAPS J.* 2019 Apr 29;21(4):61.
 - 166) Minichmayr IK, **Zeitlinger M**. Comment on "Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients". *Clin Pharmacokinet.* 2019 Jul;58(7):981-982.
 - 167) Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, **Zeitlinger M**, Hacker M. Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. *Mol Imaging Biol.* 2020 Feb;22(1):47-65.
 - 168) Ullah S, Matzneller P, **Zeitlinger M**, Fuhr U, Taubert M. A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess

- tissue exposure. *Naunyn Schmiedebergs Arch Pharmacol.* 2019 Sep;392(9):1097-1106.
- 169) Coleman JJ, Samer C, **Zeitlinger M**, van Agtmael M, Rongen GA, Marquet P, Simon T, Singer D, Manolopoulos VG, Böttiger Y. The European Association for Clinical Pharmacology and Therapeutics-25 years' young and going strong. *Eur J Clin Pharmacol.* 2019 Jun;75(6):743-750.
 - 170) Dorn C, Petroff D, Neumann N, Kratzer A, El-Najjar N, Dietrich A, Kloft C, **Zeitlinger M**, Kees MG, Kees F, Wrigge H, Simon P. Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial. *J Antimicrob Chemother.* 2019 Aug 1;74(8):2473.
 - 171) Simon P, Petroff D, Dorn C, Ehmann L, Kloft C, Prettin C, Dietrich A, **Zeitlinger M**, Kees F, Wrigge H. Measurement of soft tissue drug concentrations in morbidly obese and non-obese patients - A prospective, parallel group, open-labeled, controlled, phase IV, single center clinical trial. *Contemp Clin Trials Commun.* 2019 May 10;15:100375.
 - 172) Abufaraj M, Grubmüller B, **Zeitlinger M**, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M. Prospective evaluation of the performance of [(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. *Eur J Nucl Med Mol Imaging.* 2019 Sep;46(10):2169-2177.
 - 173) Nowak H, Weidemann C, Martini S, Oesterreicher ZA, Dorn C, Adamzik M, Kees F, **Zeitlinger M**, Rahmel T. Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. *J Antimicrob Chemother.* 2019 Sep 1;74(9):2681-2689.
 - 174) **Zeitlinger M**. A pragmatic trial in bone and joint infection. *Lancet Infect Dis.* 2019 Aug;19(8):804-805.
 - 175) Oesterreicher Z, Eberl S, **Zeitlinger M**. Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood. *Infection.* 2020 Feb;48(1):65-73.
 - 176) Andreas M, **Zeitlinger M**, Shabanian S, Wisser W, Thell R, Edlinger-Stanger M, Maier-Salamon A, Jaeger W, Kocher A, Laufer G, Hiesmayr JM, Hutschala D. Early Antibiotic Prophylaxis Prior to Bypass Surgery Improves Tissue Penetration. *Thorac Cardiovasc Surg.* 2020 Dec;68(8):669-673.
 - 177) Bauer M, **Zeitlinger M**, Langer O. Pharmacokinetic imaging with radiolabelled molecularly targeted anticancer drugs. *J Nucl Med.* 2020 Feb;61(2):306.
 - 178) Schoergenhofer C, Matzneller P, Muelbacher J, Hell L, **Zeitlinger M**, Jilma B. PCSK9 decreases during Experimental Endotoxemia. *J Intern Med.* 2020 Mar;287(3):333-335.
 - 179) Nussbaumer-Pröll AK, Eberl S, Reiter B, Stimpfl T, Jäger W, Poschner S, **Zeitlinger M**. Impact of thrombocytes, on bacterial growth and antimicrobial activity of selected antibiotics. *Eur J Clin Microbiol Infect Dis.* 2020 Mar;39(3):593-597.
 - 180) Hernández Lozano I, Bauer M, Wulkersdorfer B, Traxl A, Philippe C, Weber M, Häusler S, Stieger B, Jäger W, Mairinger S, Wanek T, Hacker M, **Zeitlinger M**, Langer O. Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [(11)C]Tariquidar and PET in Humans and Mice. *Mol Pharm.* 2020 Jan 6;17(1):316-326.
 - 181) Nussbaumer-Pröll AK, Eberl S, Reiter B, Stimpfl T, Dorn C, **Zeitlinger M**. Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections. *J Antimicrob Chemother.* 2020 Mar 1;75(3):593-599.

- 182) Wulkersdorfer B, Bauer M, Karch R, Stefanits H, Philippe C, Weber M, Czech T, Menet MC, Declèves X, Hainfellner JA, Preusser M, Hacker M, **Zeitlinger M**, Müller M, Langer O. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. *EJNMMI Res.* 2019 Dec 12;9(1):110.
- 183) **Zeitlinger M**, Berger A. Prophylactic antibiotics in prevention of infection after operative vaginal or caesarean delivery -number-needed-to-treat with focus on endpoints. *Clin Microbiol Infect.* 2020 Apr;26(4):404-405.
- 184) Tobudic S, Prager I, Kussmann M, Obermüller M, Ursli M, **Zeitlinger M**, Wiesholzer M, Burgmann H, Poepl W, Reznicek G. Compatibility of aztreonam in four commercial peritoneal dialysis fluids. *Sci Rep.* 2020 Feb 4;10(1):1788.
- 185) Iqbal K, Broeker A, Nowak H, Rahmel T, Nussbaumer-Pröll A, Österreicher Z, **Zeitlinger M**, Wicha SG. A pharmacometric approach to define target site-specific breakpoints for bacterial killing and resistance suppression integrating microdialysis, time-kill curves and heteroresistance data: a case study with moxifloxacin. *Clin Microbiol Infect.* 2020 Sep;26(9):1255.e1-1255.e8.
- 186) Al Jalali V, **Zeitlinger M**. Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents. *Clin Pharmacokinet.* 2020 Jul;59(7):827-847. Dorn C, Schießler S, Wulkersdorfer B, Hitzentbichler F, Kees MG, Zeitlinger M. Determination of free clindamycin, flucloxacillin or tedizolid in plasma: Pay attention to physiological conditions when using ultrafiltration. *Biomed Chromatogr.* 2020 Jun;34(6):e4820.
- 187) Weixlbaumer V, Draxler L, **Zeitlinger M**, Prantl B. From St. John's wort to tomato and from Rhodiola to cranberry : A review of phytotherapy and some examples. *Wien Klin Wochenschr.* 2020 May;132(9-10):253-259.
- 188) Ullah S, Beer R, Fuhr U, Taubert M, **Zeitlinger M**, Kratzer A, Dorn C, Arshad U, Kofler M, Helbok R. Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics. *Neurocrit Care.* 2020 Dec;33(3):740-748. doi: 10.1007/s12028-020-00947-x.
- 189) Simon P, Busse D, Petroff D, Dorn C, Ehmann L, Hochstädt S, Girschbach F, Dietrich A, **Zeitlinger M**, Kees F, Kloft C, Wrigge H. Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study. *J Clin Med.* 2020 Apr 9;9(4):1067. doi: 10.3390/jcm9041067.
- 190) Ehmann L, Simon P, Busse D, Petroff D, Dorn C, Huisinga W, Dietrich A, **Zeitlinger M**, Wrigge H, Kloft C. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy. *Clin Microbiol Infect.* 2020 Sep;26(9):1222-1228. doi: 10.1016/j.cmi.2020.04.009.
- 191) Jorda A, **Zeitlinger M**. Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review. *Clin Pharmacokinet.* 2020 Sep;59(9):1071-1084. doi: 10.1007/s40262-020-00892-0.
- 192) Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, **Zeitlinger M**, De Waele JJ, Roberts JA; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. *Intensive Care Med.* 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1.

- 193) Matzneller P, Ngougni Pokem P, Capron A, Lackner E, Wulkersdorfer B, Nussbaumer-Pröll A, Österreicher Z, Duchek M, Van de Velde S, Wallemacq PE, Mouton JW, Van Bambeke F, **Zeitlinger M**. Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. *J Antimicrob Chemother*. 2020 Sep 1;75(9):2650-2656. doi: 10.1093/jac/dkaa176.
- 194) **Zeitlinger M**, Koch BCP, Bruggemann R, De Cock P, Felton T, Hites M, Le J, Luque S, MacGowan AP, Marriott DJE, Muller AE, Nadrah K, Paterson DL, Standing JF, Telles JP, Wölfl-Duchek M, Thy M, Roberts JA; PK/PD of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology, Infectious Diseases (ESCMID). Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. *Clin Pharmacokinet*. 2020 Oct;59(10):1195-1216. doi: 10.1007/s40262-020-00924-9.
- 195) Nussbaumer-Pröll A, **Zeitlinger M**. Use of Supplemented or Human Material to Simulate PD Behavior of Antibiotics at the Target Site In Vitro. *Pharmaceutics*. 2020 Aug 14;12(8):773. doi: 10.3390/pharmaceutics12080773.
- 196) Tzotzos SJ, Fischer B, Fischer H, **Zeitlinger M**. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. *Crit Care*. 2020 Aug 21;24(1):516. doi: 10.1186/s13054-020-03240-7.
- 197) Bauer M, Bamming K, Pichler V, Weber M, Binder S, Maier-Salamon A, Tahir A, Jäger W, Haslacher H, Tournier N, Hacker M, **Zeitlinger M**, Langer O. Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. *Clin Pharmacol Ther*. 2021 Mar;109(3):754-761. doi: 10.1002/cpt.2052.
- 198) Boehm T, Karer M, Matzneller P, Buchtele N, Ratzinger F, Petroczi K, Schoergenhofer C, Schwameis M, Burgmann H, **Zeitlinger M**, Jilma B. Human diamine oxidase is readily released from activated neutrophils ex vivo and in vivo but is rarely elevated in bacteremic patients. *Int J Immunopathol Pharmacol*. 2020 Jan-Dec;34:2058738420954945. doi: 10.1177/2058738420954945.
- 199) Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, **Zeitlinger M**, Nagata TD. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis*. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3.
- 200) Al Jalali V, Matzneller P, Wulkersdorfer B, Chou S, Bahmany S, Koch BCP, **Zeitlinger M**. Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers. *Antimicrob Agents Chemother*. 2020 Dec 16;65(1):e01375-20. doi: 10.1128/AAC.01375-20.
- 201) Dal-Ré R, Banzi R, Georgin-Lavialle S, Porcher R, Sofat R, **Zeitlinger M**, Rosendaal FR. Remdesivir for COVID-19 in Europe: will it provide value for money? *Lancet Respir Med*. 2021 Feb;9(2):127-128. doi: 10.1016/S2213-2600(20)30568-3.
- 202) Simon P, Petroff D, Busse D, Heyne J, Girschbach F, Dietrich A, Kratzer A, **Zeitlinger M**, Kloft C, Kees F, Wrigge H, Dorn C. Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients-A Controlled Clinical Trial. *Antibiotics (Basel)*. 2020 Dec 21;9(12):931. doi: 10.3390/antibiotics9120931.
- 203) Opfermann P, Marhofer P, Hopkins PM, Columb MO, Zadrazil M, Stimpfl T, Marhofer M, **Zeitlinger M**. Generic versus reference listed ropivacaine for peripheral nerve blockade: A randomised, triple-blinded, crossover, equivalence study in volunteers.

- Eur J Anaesthesiol. 2021 Aug 1;38(Suppl 2):S113-S120. doi: 10.1097/EJA.0000000000001424.
- 204) Bauer M, Barna S, Blaickner M, Prosenz K, Bamminger K, Pichler V, Tournier N, Hacker M, **Zeitlinger M**, Karanikas G, Langer O. Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [¹¹C]Metoclopramide. *Mol Imaging Biol*. 2021 Apr;23(2):180-185. doi: 10.1007/s11307-021-01582-4.
 - 205) Hosmann A, Angelmayr C, Hopf A, Rauscher S, Brugger J, Ritscher L, Bohl I, Schnackenburg P, Engel A, Plöchl W, **Zeitlinger M**, Reinprecht A, Rössler K, Gruber A. Detrimental effects of intrahospital transport on cerebral metabolism in patients suffering severe aneurysmal subarachnoid hemorrhage. *J Neurosurg*. 2021 Mar 12:1-8. doi: 10.3171/2020.8.JNS202280.
 - 206) Busse D, Schaeftlein A, Solms A, Ilia L, Michelet R, **Zeitlinger M**, Huisinga W, Kloft C. Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin. *Pharm Res*. 2021 Mar;38(3):381-395. doi: 10.1007/s11095-021-02994-1.
 - 207) Jorda A, **Zeitlinger M**. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. *Expert Rev Clin Pharmacol*. 2021 Apr 26:1-15. doi: 10.1080/17512433.2021.1917375.
 - 208) Dorn C, Petroff D, Stoelzel M, Kees MG, Kratzer A, Dietrich A, Kloft C, **Zeitlinger M**, Kees F, Wrigge H, Simon P. Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. *J Antimicrob Chemother*. 2021 Jul 15;76(8):2114-2120. doi: 10.1093/jac/dkab143.
 - 209) **Zeitlinger M**, Bauer M, Reindl-Schwaighofer R, Stoekenbroek RM, Lambert G, Berger-Sieczkowski E, Lagler H, Oesterreicher Z, Wulkersdorfer B, Lührs P, Galabova G, Schwenke C, Mader RM, Medori R, Landlinger C, Kutzelnigg A, Staffler G. A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. *Eur J Clin Pharmacol*. 2021 Oct;77(10):1473-1484. doi:10.1007/s00228-021-03149-2.
 - 210) Wulkersdorfer B, Wicha SG, Kurdina E, Carrion Carrera SF, Matzneller P, Al Jalali V, Vossen MG, Riesenhuber S, Lackner E, Dorn C, **Zeitlinger M**. Protein binding of clindamycin in vivo by means of intravascular microdialysis in healthy volunteers. *J Antimicrob Chemother*. 2021 Jul 15;76(8):2106-2113. doi:10.1093/jac/dkab140.
 - 211) **Zeitlinger M**, Idzko M. Inhaled budesonide for early treatment of COVID-19. *Lancet Respir Med*. 2021 Jul;9(7):e59. doi: 10.1016/S2213-2600(21)00215-0.
 - 212) Al Jalali V, Wölfl-Duchek M, Taubert M, Matzneller P, Lackner E, Dorn C, Kratzer A, Wulkersdorfer B, Österreicher Z, **Zeitlinger M**. Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study. *J Antimicrob Chemother*. 2021 Aug 12;76(9):2342-2351. doi: 10.1093/jac/dkab166.
 - 213) Kallab M, Schuetzenberger K, Hommer N, Schäfer BJ, Schmidl D, Bergmeister H, **Zeitlinger M**, Tan A, Jansook P, Loftsson T, Stefansson E, Garhöfer G. Bio-Distribution and Pharmacokinetics of Topically Administered γ -Cyclodextrin Based Eye Drops in Rabbits. *Pharmaceuticals (Basel)*. 2021 May 18;14(5):480. doi: 10.3390/ph14050480.
 - 214) **Zeitlinger M**. EACPT Virtual Meeting 2021. *Eur J Clin Pharmacol*. 2021 Jun;77(Suppl 1):1-42. doi: 10.1007/s00228-021-03164-3.
 - 215) Al Jalali V, Scherzer S, **Zeitlinger M**. Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines. *Clin Microbiol Infect*. 2021 Oct;27(10):1529-1530. doi: 10.1016/j.cmi.2021.06.022.
 - 216) El Biali M, Karch R, Philippe C, Haslacher H, Tournier N, Hacker M, **Zeitlinger M**, Schmidl D, Langer O, Bauer M. ABCB1 and ABCG2 Together Limit the Distribution of

- ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure. *Front Pharmacol.* 2021 Jun 16;12:698966. doi:10.3389/fphar.2021.698966.
- 217) Matzneller P, Oesterreicher Z, Wulkersdorfer B, Jalali VA, Mascher D, Mascher H, **Zeitlinger M**. Microdialysis as a potential tool for comparative assessment of tissue pharmacokinetics of two different patches containing lidocaine: A crossover pilot study. *Int J Clin Pharmacol Ther.* 2021 Sep;59(9):603-609. doi: 10.5414/CP203922.
- 218) Vossen MG, Pferschy S, Milacek C, Haidinger M, Karolyi M, Vass Z, Burgmann H, Maier-Salamon A, Wicha SG, Jäger W, **Zeitlinger M**, Stimpfl T, Wittek T, Thalhammer F. In vivo/ in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model. *Front Pharmacol.* 2021 Jun 24;12:702455. doi: 10.3389/fphar.2021.702455.
- 219) Edlinger-Stanger M, Al Jalali V, Andreas M, Jäger W, Böhmendorfer M, **Zeitlinger M**, Hutschala D. Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an In Vivo Microdialysis Study. *Antimicrob Agents Chemother.* 2021 Sep 17;65(10):e0067921. doi: 10.1128/AAC.00679-21.
- 220) Schroepl S, Burau D, Muench HG, Derendorf H, **Zeitlinger M**, Genzel-Boroviczeny O, Adam D, Kloft C. Microdialysis sampling to monitor target-site vancomycin concentrations in septic infants: a feasible way to close the knowledge gap. *Int J Antimicrob Agents.* 2021 Oct;58(4):106405. doi:10.1016/j.ijantimicag.2021.106405.
- 221) Bauer M, Lackner E, Matzneller P, Al Jalali V, Pajenda S, Ling V, Böhler C, Braun W, Braun R, Boesch M, Brunner PM, **Zeitlinger M**. Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis. *Front Med (Lausanne).* 2021 Jul 16;8:712511. doi: 10.3389/fmed.2021.712511.
- 222) Guntner AS, Buchberger W, Hosmann A, Mercea PA, Koren J, Reinprecht A, **Zeitlinger M**, Herta J. Quantitative analysis of human brain microdialysate for target site pharmacokinetics of major anesthetics ketamine, midazolam and propofol. *J Pharm Biomed Anal.* 2021 Oct 25;205:114289. doi: 10.1016/j.jpba.2021.114289.
- 223) Hosmann A, Ritscher L, Burgmann H, Al Jalali V, Wulkersdorfer B, Wölfl-Duchek M, Sanz Codina M, Jäger W, Poschner S, Plöchl W, Reinprecht A, Rössler K, Gruber A, **Zeitlinger M**. Meropenem concentrations in brain tissue of neurointensive care patients exceed CSF levels. *J Antimicrob Chemother.* 2021 Oct 11;76(11):2914-2922. doi: 10.1093/jac/dkab286.
- 224) Karer M, Stiasny K, **Zeitlinger M**, Jilma B. Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients? *Blood Coagul Fibrinolysis.* 2021 Sep 1;32(6):423-424. doi: 10.1097/MBC.0000000000001048.
- 225) Busse D, Simon P, Petroff D, Dorn C, Schmitt L, Bindellini D, Kratzer A, Dietrich A, **Zeitlinger M**, Huisinga W, Michelet R, Wrigge H, Kloft C. Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics. *Pharmaceutics.* 2021 Aug 31;13(9):1380. doi: 10.3390/pharmaceutics13091380.
- 226) Eichler HG, Trusheim M, Schwarzer-Daum B, Larholt K, **Zeitlinger M**, Brunninger M, Sherman M, Strutton D, Hirsch G. Precision Reimbursement for Precision Medicine: Using Real-World Evidence to Evolve From Trial-and-Project to Track-and-Pay to Learn-and-Predict. *Clin Pharmacol Ther.* 2022 Jan;111(1):52-62. doi: 10.1002/cpt.2471.
- 227) Lagler H, Bangert C, Quint T, Österreicher Z, Nussbaumer-Pröll A, Eberl S, Weber M, Karer M, Sommer MOA, **Zeitlinger M**. Comparison of non-invasive *Staphylococcus*

- aureus sampling methods on lesional skin in patients with atopic dermatitis. *Eur J Clin Microbiol Infect Dis*. 2022 Feb;41(2):245-252. doi: 10.1007/s10096-021-04365-5.
- 228) Jorda A, Siller-Matula JM, **Zeitlinger M**, Jilma B, Gelbenegger G. Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis. *Clin Pharmacol Ther*. 2022 Mar;111(3):614-623. doi: 10.1002/cpt.2504.
- 229) Busse D, Simon P, Schmitt L, Petroff D, Dorn C, Dietrich A, **Zeitlinger M**, Huisinga W, Michelet R, Wrigge H, Kloft C. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. *Clin Pharmacokinet*. 2022 May;61(5):655-672. doi: 10.1007/s40262-021-01070-6.
- 230) Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, **Zeitlinger M**, Echols R. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. *Expert Rev Anti Infect Ther*. 2022 May;20(5):707-719. doi: 10.1080/14787210.2022.2020099.
- 231) van Os W, **Zeitlinger M**. Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches. *Antibiotics (Basel)*. 2021 Dec 4;10(12):1485. doi: 10.3390/antibiotics10121485.
- 232) Dillinger T, Sheibani-Tezerji R, Pulverer W, Stelzer I, Hassler MR, Scheibelreiter J, Pérez Malla CU, Kuroll M, Domazet S, Redl E, Ely S, Brezina S, Tiefenbacher A, Rebhan K, Hübner N, Grubmüller B, Mitterhauser M, Hacker M, Weinhaeusel A, Simon J, **Zeitlinger M**, Gsur A, Kramer G, Shariat SF, Kenner L, Egger G. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. *Mol Cancer*. 2022 Jan 3;21(1):7. doi:10.1186/s12943-021-01445-0.
- 233) Oesterreicher Z, Eberl S, Wulkersdorfer B, Matzneller P, Eder C, van Duijn E, Vaes WHJ, Reiter B, Stimpfl T, Jäger W, Nussbaumer-Proell A, Marhofer D, Marhofer P, Langer O, **Zeitlinger M**. Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. *Clin Pharmacokinet*. 2022 May;61(5):697-707. doi:10.1007/s40262-021-01091-1.
- 234) Schulz J, Michelet R, Joseph JF, **Zeitlinger M**, Schumacher F, Mikus G, Kloft C. A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications. *J Pharm Biomed Anal*. 2022 Feb 20;210:114551. doi: 10.1016/j.jpba.2021.114551.
- 235) Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblishke M, Mandl P, Kornek B, Simader E, Radner H, Perkmann T, Haslacher H, Mayer M, Hofer P, Redlich K, Husar-Memmer E, Fritsch-Stork R, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, **Zeitlinger M**, Heinz LX, Aletaha D. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. *Ann Rheum Dis*. 2022 May;81(5):687-694. doi:10.1136/annrheumdis-2021-221558.
- 236) Jorda A, Armogida M, Lackner E, Saikumar S, Sucharski F, Weber M, **Zeitlinger M**. Diclofenac in vitro microdialysis study comparing different experimental set-ups to improve quantitative recovery. *Basic Clin Pharmacol Toxicol*. 2022 Apr;130(4):468-480. doi: 10.1111/bcpt.13709.
- 237) Wölfl-Duchek M, Bergmann F, Jorda A, Weber M, Müller M, Seitz T, Zoufaly A, Strassl R, **Zeitlinger M**, Herkner H, Schnidar H, Anderle K, Derhaschnig U.

- Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Detection Tests Using Oral, Anterior Nasal, and Nasopharyngeal Swabs: a Diagnostic Accuracy Study. *Microbiol Spectr.* 2022 Feb 23;10(1):e0202921. doi: 10.1128/spectrum.02029-21.
- 238) Jorda A, Wulkersdorfer B, Schörgenhofer C, Matzneller P, Al Jalali V, Bauer M, Wölf-Duchek M, Lackner E, Dorn C, Jilma B, Zeitlinger M. Influence of tedizolid on the cytokine response to the endotoxin challenge in healthy volunteers: a cross-over trial. *J Antimicrob Chemother.* 2022 Apr 27;77(5):1424-1431. doi: 10.1093/jac/dkac039.
 - 239) Jorda A, Kussmann M, Kolenchery N, Siller-Matula JM, **Zeitlinger M**, Jilma B, Gelbenegger G. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis. *Front Immunol.* 2022 Feb 7;13:817829. doi:10.3389/fimmu.2022.817829.
 - 240) Nussbaumer-Pröll AK, Eberl S, Welte R, Gasperetti T, Marx J, Bellmann R, **Zeitlinger M**. Comparison of Antimycotic Activity of Originator and Generics of Voriconazole and Anidulafungin against Clinical Isolates of *Candida albicans* and *Candida glabrata*. *J Fungi (Basel).* 2022 Feb 17;8(2):195. doi: 10.3390/jof8020195.
 - 241) Sanz Codina M, Zeitlinger M. Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review. *Clin Pharmacokinet.* 2022 May;61(5):593-617. doi: 10.1007/s40262-021-01102-1.
 - 242) Nussbaumer-Pröll A, Eberl S, Kurdina E, Schmidt L, **Zeitlinger M**. Challenging T > MIC Using Meropenem vs. *Escherichia coli* and *Pseudomonas aeruginosa*. *Front Pharmacol.* 2022 Apr 1;13:840692. doi:10.3389/fphar.2022.840692.
 - 243) Cicali B, Schmidt S, **Zeitlinger M**, Brown JD. Macrolide Treatment Failure due to Drug-Drug Interactions: Real-World Evidence to Evaluate a Pharmacological Hypothesis. *Pharmaceutics.* 2022 Mar 25;14(4):704. doi: 10.3390/pharmaceutics14040704.
 - 244) Weiss A, Delavenne E, Matias C, Lagler H, Simon D, Li P, Hansen JU, Dos Santos TP, Jana B, Priemel P, Bangert C, Bauer M, Eberl S, Nussbaumer-Pröll A, Anne Österreicher Z, Matzneller P, Quint T, Weber M, Nielsen HM, Rades T, Johansen HK, Westh H, Kim W, Mylonakis E, Friis C, Guardabassi L, Pace J, Lundberg CV, M'Zali F, Butty P, Sørensen N, Nielsen HB, Toft-Kehler R, Guttman-Yassky E, Stingl G, **Zeitlinger M**, Sommer M. Topical niclosamide (ATx201) reduces *Staphylococcus aureus* colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial. *Clin Transl Med.* 2022 May;12(5):e790. doi:10.1002/ctm2.790.
 - 245) Busse D, Simon P, Petroff D, El-Najjar N, Schmitt L, Bindellini D, Dietrich A, **Zeitlinger M**, Huisinga W, Michelet R, Wrigge H, Kloft C. High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients. *Antimicrob Agents Chemother.* 2022 Jun 21;66(6):e0230221. doi: 10.1128/aac.02302-21.
 - 246) Salmanton-García J, Stewart FA, Heringer S, Koniordou M, Álvarez-Barco E, Argyropoulos CD, Themistocleous SC, Valle-Simón P, Spivak O, Součková L, Merakou C, Amélia Mendonça M, Joanna Davis R, Maria Azzini A, Askling HH, Vene S, Van Damme P, Steinbach A, Shiamakkides G, Seidel D, Olesen OF, Noura E, Macken A, Luís C, Leckler J, Launay O, Isitt C, Hellemans M, Frías-Iniesta J, Di Marzo R, Carcas AJ, Boustras G, Borobia AM, Barta I, Albus K, Akova M, Ochando J, Cohen-Kandli M, Jane Cox R, Husa P, Jancoriene L, Mallon P, Marques L, Mellinghoff SC, Naució P, Tacconelli E, Tóth K, Zaoutis TE, **Zeitlinger M**, Cornely OA, Pana ZD; VACCCELERATE consortium. VACCCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. *Vaccine.* 2022 Jul 29;40(31):4090-4097. doi: 10.1016/j.vaccine.2022.05.022.
 - 247) Iqbal K, Rohde H, Huang J, Tikiso T, Amann LF, **Zeitlinger M**, Wicha SG. A pharmacokinetic-pharmacodynamic (PKPD) model-based analysis of tedizolid against

- enterococci using the hollow-fibre infection model. *J Antimicrob Chemother.* 2022 Aug 25;77(9):2470-2478. doi: 10.1093/jac/dkac183.
- 248) Bulman ZP, Wicha SG, Nielsen EI, Lenhard JR, Nation RL, Theuretzbacher U, Derendorf H, Tängdén T, **Zeitlinger M**, Landersdorfer CB, Bulitta JB, Friberg LE, Li J, Tsuji BT; International Society of Anti-Infective Pharmacology; European Society of Clinical Microbiology and Infectious Diseases Pharmacokinetics and Pharmacodynamics of Anti-Infectives Study Group; International Society of Antimicrobial Chemotherapy Anti-Infective Pharmacology Working Group. Research priorities towards precision antibiotic therapy to improve patient care. *Lancet Microbe.* 2022 Jun 28:S2666-5247(22)00121-5. doi: 10.1016/S2666-5247(22)00121-5.
 - 249) Alshaer MH, Barlow B, Maranchick N, Moser M, Gramss L, Burgmann H, Jalali VA, Wölfl-Duchek M, Jäger W, Poschner S, Plöchl W, Reinprecht A, Rössler K, Gruber A, **Zeitlinger M**, Peloquin CA, Hosmann A. Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue. *Antimicrob Agents Chemother.* 2022 Aug 16;66(8):e0043822. doi: 10.1128/aac.00438-22.
 - 250) Ahmed H, Bergmann F, **Zeitlinger M**. Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences. *Antibiotics (Basel).* 2022 Jul 8;11(7):923. doi: 10.3390/antibiotics11070923.
 - 251) Bergmann F, Matzneller P, Weber M, Yeghiazaryan L, Fuereder T, Weber T, **Zeitlinger M**. Perception of clinical research among patients and healthy volunteers of clinical trials. *Eur J Clin Pharmacol.* 2022 Oct;78(10):1647-1655. doi: 10.1007/s00228-022-03366-3.
 - 252) Karolyi M, Pawelka E, Omid S, Koenig F, Kauer V, Rumpf B, Hoepler W, Kuran A, Laferl H, Seitz T, Traugott M, Rathkolb V, Mueller M, Abrahamowicz A, Schoergenhofer C, Hecking M, Assinger A, Wenisch C, **Zeitlinger M**, Jilma B, Zoufaly A. Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT). *Front Pharmacol.* 2022 Jul 22;13:870493. doi:10.3389/fphar.2022.870493.
 - 253) Dorn C, Petroff D, Kratzer A, Kees F, Kloft C, **Zeitlinger M**, Wrigge H, Simon P. Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis. *Eur J Drug Metab Pharmacokinet.* 2022 Sep;47(5):749-755. doi: 10.1007/s13318-022-00789-2.
 - 254) Helfer VE, Zavascki AP, **Zeitlinger M**, de Araújo BV, Dalla Costa T. Population Pharmacokinetic Modeling and Probability of Target Attainment of Ceftaroline in Brain and Soft Tissues. *Antimicrob Agents Chemother.* 2022 Sep 20;66(9):e0074122. doi: 10.1128/aac.00741-22.
 - 255) Ngougni Pokem P, Matzneller P, Vervaeke S, Wittebole X, Goeman L, Coessens M, Cottone E, Capron A, Wulkersdorfer B, Wallemacq P, Mouton JW, Muller AE, **Zeitlinger M**, Laterre PF, Tulkens PM, Van Bambeke F. Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications. *J Antimicrob Chemother.* 2022 Aug 26:dkac286. doi: 10.1093/jac/dkac286.
 - 256) Bergmann F, Stadlmayr S, Millesi F, **Zeitlinger M**, Naghilou A, Radtke C. The properties of native Trichonephila dragline silk and its biomedical applications. *Biomater Adv.* 2022 Sep;140:213089. doi:10.1016/j.bioadv.2022.213089.
 - 257) Bergmann F, Wulkersdorfer B, Oesterreicher Z, Bauer M, Al Jalali V, Nussbaumer-Pröll A, Wölfl-Duchek M, Jorda A, Lackner E, Reiter B, Stimpfl T, Ballarini N, König F, **Zeitlinger M**. Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers. *J Antimicrob Chemother.* 2022 Aug 30:dkac285. doi: 10.1093/jac/dkac285.

- 258) Jorda A, **Zeitlinger M**. Interrupting methotrexate to improve immunity after COVID-19 booster vaccination: is it really worth it? *Lancet Respir Med*. 2022 Sep;10(9):e80. doi: 10.1016/S2213-2600(22)00271-5.
- 259) Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Koblishke M, Hommer N, Wagner A, Mayer M, Schubert L, Hartl L, Kozbial K, Hofer P, Kartnig F, Hummel T, Kerschbaumer A, Deimel T, Puchner A, Gudipati V, Thalhammer R, Munda P, Uyanik-Ünal K, Zuckermann A, Novacek G, Reiberger T, Garner-Spitzer E, Reindl-Schwaighofer R, Kain R, Winkler S, Smolen JS, Stiasny K, Fischer GF, Perkmann T, Haslacher H, **Zeitlinger M**, Wiedermann U, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. *Nat Commun*. 2022 Sep 12;13(1):5362. doi: 10.1038/s41467-022-33036-y. Langer O, Song J, Choi MS, Lackner E, Bergmann F, Yeo CS, Kwon M, Kwon M, Shim JH, R Dueker S, Zeitlinger M, Bauer M. Accelerator mass spectrometry for quantification of micro- and therapeutic-dose diclofenac in microdialysis samples. *Bioanalysis*. 2022 Aug;14(16):1111-1122. doi: 10.4155/bio-2022-0064.
- 260) Schulz J, Michelet R, Zeitlinger M, Mikus G, Kloft C. Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide. *Pharm Res*. 2022 Nov;39(11):2991-3003. doi:10.1007/s11095-022-03292-0.
- 261) Jorda A, Wulkersdorfer B, Schoergenhofer C, Matzneller P, Al Jalali V, Bauer M, Wölfl-Duchek M, Lackner E, Dorn C, Jilma B, Zeitlinger M. Effect of the human endotoxin challenge on tedizolid tissue penetration. *Br J Clin Pharmacol*. 2023 Jan;89(1):416-420. doi: 10.1111/bcp.15564.
- 262) Mairinger S, Hernández-Lozano I, Zeitlinger M, Ehrhardt C, Langer O. Nuclear medicine imaging methods as novel tools in the assessment of pulmonary drug disposition. *Expert Opin Drug Deliv*. 2022 Dec;19(12):1561-1575. doi:10.1080/17425247.2022.2137143.
- 263) Schulz J, Michelet R, Zeitlinger M, Mikus G, Kloft C. Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans. *Pharm Res*. 2022 Dec;39(12):3279-3291. doi:10.1007/s11095-022-03407-7.
- 264) Sieghart D, Hana CA, Haslacher H, Perkmann T, Heinz LX, Fedrizzi C, Anderle K, Wiedermann U, Condur I, Drapalik S, Steinbrecher H, Mrak D, Mucher P, Hasenoehrl T, Zrdavkovic A, Wagner B, Palma S, Jordakieva G, Jorda A, Firbas C, Wagner A, Haiden N, Bergmann F, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort Study. *Clin Infect Dis*. 2023 Mar 4;76(5):816-823. doi: 10.1093/cid/ciac840.
- 265) Sanz-Codina M, Wicha SG, Wulkersdorfer B, Al Jalali V, Van Os W, Vossen MG, Bauer M, Lackner E, Dorn C, Zeitlinger M. Comparison of ultrafiltration and microdialysis for ceftriaxone protein-binding determination. *J Antimicrob Chemother*. 2023 Feb 1;78(2):380-388. doi: 10.1093/jac/dkac400.
- 266) Raicu AM, Fay JC, Rohner N, Zeitlinger J, Arnosti DN. Off the deep end: What can deep learning do for the gene expression field? *J Biol Chem*. 2023 Jan;299(1):102760. doi: 10.1016/j.jbc.2022.102760.
- 267) Al Jalali V, Bauer M, Wölfl-Duchek M, Sarhan M, Wicha SG, Poschner S, Jäger W, König F, Male C, Zeitlinger M. Pilot Pharmacokinetic Study in Healthy Adults Using Intravascular Microdialysis Catheters Modified for Use in Paediatric Patients to Assess Vancomycin Blood Levels. *Clin Pharmacokinet*. 2023 Jan;62(1):77-87. doi: 10.1007/s40262-022-01190-7.

- 268) Radner H, Sieghart D, Jorda A, Fedrizzi C, Hasenöhl T, Zdravkovic A, Redlberger-Fritz M, Puchhammer-Stoeckl E, Anderle K, Bergmann F, Firbas C, Jordakieva G, Wagner B, Haslacher H, Perkmann T, Heinz LX, Bonelli M, Crevenna R, Aletaha D, Zeitlinger M. Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers. *Clin Microbiol Infect.* 2023 May;29(5):635-641. doi: 10.1016/j.cmi.2022.12.008.
- 269) Bernthal NM, Randall RL, Zeitlinger LN, Geiger EJ, Healey JH. Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor. *Case Rep Orthop.* 2022 Dec 3;2022:7768764. doi: 10.1155/2022/7768764.
- 270) Yusuf E, Zeitlinger M, Meylan S. A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship. *J Antimicrob Chemother.* 2023 Feb 1;78(2):338-345. doi: 10.1093/jac/dkac413.
- 271) Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. *Crit Care.* 2023 Jan 10;27(1):9. doi:10.1186/s13054-022-04205-8.
- 272) Rau C, Auer-Hackenberg L, Deubzer HE, Schwabel E, Jaros M, Diederichs A, Lehnbecher T, Holm M, von Linstow ML, Martin L, Dinges SS, Rothensteiner M, Siepermann M, Strenger V, von Both U, Teig N, Brinkmann F, Leeb F, Zeitlinger M, Kobbe R, Götzinger F. Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series. *Pediatr Infect Dis J.* 2023 Feb 1;42(2):125-129. Doi 10.1097/INF.0000000000003773.
- 273) Al Jalali V, Wasinger G, Rasul S, Grubmüller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G, Zeitlinger M. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer. *J Nucl Med.* 2023 Jun;64(6):863-868. doi:10.2967/jnumed.122.264981.
- 274) Nussbaumer-Pröll A, Eberl S, Belley A, Knechtle P, Huband MD, Huynh HK, Zeitlinger M. Impact of surfactants and other body fluids on in vitro activity of a novel β -lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of *Klebsiella pneumoniae*. *J Antibiot (Tokyo).* 2023 Mar;76(3):183-189. doi: 10.1038/s41429-022-00592-w.
- 275) Mairinger S, Hernández-Lozano I, Filip T, Löbsch M, Stanek J, Zeitlinger M, Hacker M, Tournier N, Wanek T, Ehrhardt C, Langer O. Influence of P-glycoprotein on pulmonary disposition of the model substrate [¹¹C]metoclopramide assessed by PET imaging in rats. *Eur J Pharm Sci.* 2023 Apr 1;183:106404. doi:10.1016/j.ejps.2023.106404.
- 276) Eichler HG, Kossmeier M, Zeitlinger M, Schwarzer-Daum B. Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan

- drug reimbursement. *Front Pharmacol.* 2023 Jan 26;14:1074512. doi: 10.3389/fphar.2023.1074512.
- 277) Mair MJ, Maj-Hes A, Nussbaumer-Pröll A, Puhr R, Christenheit A, Troch M, Puhr HC, Starzer AM, Steindl A, Eberl S, Haslacher H, Perkmann T, Minichsdorfer C, Prager GW, Lamm WW, Berghoff AS, Kiesewetter B, Zeitlinger M, Preusser M, Raderer M. Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo- controlled phase 2 trial. *Infect Agent Cancer.* 2023 Feb 12;18(1):9. doi: 10.1186/s13027-023-00487-x.
- 278) Hernández-Lozano I, Mairinger S, Filip T, Löbsch M, Stanek J, Kuntner C, Bauer M, Zeitlinger M, Hacker M, Helbich TH, Wanek T, Langer O. Positron Emission Tomography-Based Pharmacokinetic Analysis To Assess Renal Transporter-Mediated Drug-Drug Interactions of Antimicrobial Drugs. *Antimicrob Agents Chemother.* 2023 Mar 16;67(3):e0149322. doi: 10.1128/aac.01493-22.
- 279) Van Bambeke F, Wicha S, Tulkens PM, Zeitlinger M. Editorial for the Special Issue "A Themed Issue in Honor of Professor Hartmut Derendorf-Outstanding Contributions in the Fields of Quantitative Clinical Pharmacology". *Antibiotics (Basel).* 2023 Feb 8;12(2):353. doi: 10.3390/antibiotics12020353.
- 280) Mairinger S, Hernández-Lozano I, Zachhuber L, Filip T, Löbsch M, Zeitlinger M, Hacker M, Ehrhardt C, Langer O. Effect of budesonide on pulmonary activity of multidrug resistance-associated protein 1 assessed with PET imaging in rats. *Eur J Pharm Sci.* 2023 May 1;184:106414. doi: 10.1016/j.ejps.2023.106414.
- 281) Zeitlinger M, Tillotson G, Echols R. Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check. *Front Pharmacol.* 2023 Feb 15;14:1150472. doi: 10.3389/fphar.2023.1150472.
- 282) Argyropoulos CD, Leckler J, Salmanton-García J, Constantinou M, Alexandrou A, Themistocleous S, Noula E, Shiamakkides G, Nearchou A, Stewart FA, Albus K, Koniordou M, Kopsidas I, Spivak O, Hellemans M, Hendrickx G, Davis RJ, Azzini AM, Simon PV, Carcas-Sansuan AJ, Askling HH, Vene S, PELLEZO JB, Álvarez-Barco E, Macken AJ, Di Marzo R, Luís C, Olesen OF, Frias Iniesta JA, Barta I, Tóth K, Akova M, Bonten MMJ, Cohen-Kandli M, Cox RJ, Součková L, Husa P, Jancoriene L, Launay O, Lundgren J, Mallon P, Arneftis C, Marques L, Naucier P, Ochando J, Tacconelli E, van Damme P, Zaoutis T, Hofstra S, Bruijning-Verhagen P, Zeitlinger M, Cornely OA, Pana ZD. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCCELERATE Toolkit. *JMIR Public Health Surveill.* 2023 Apr 3;9:e44491. doi: 10.2196/44491.
- 283) Sanz-Codina M, Bozkir HÖ, Jorda A, Zeitlinger M. Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials. *Clin Microbiol Infect.* 2023 Jul;29(7):845-857. doi: 10.1016/j.cmi.2023.03.018.
- 284) Nadvornik C, Kallab M, Hommer N, Schlatter A, Stengel T, Garhöfer G, Zeitlinger M, Eberl S, Klymiuk I, Trajanoski S, Nehr M, Makristathis A, Schmidl D, Nussbaumer-Proell A. Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects-A Pilot Study. *Antibiotics (Basel).* 2023 Mar 4;12(3):517. doi: 10.3390/antibiotics12030517.
- 285) Bergmann F, Jorda A, Blaschke A, Gabler C, Bohdan S, Nussbaumer-Pröll A, Radtke C, Zeitlinger M. Pulmonary Aspergillosis in Critically Ill COVID-19 Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study. *J Fungi (Basel).* 2023 Mar 3;9(3):315. doi: 10.3390/jof9030315.
- 286) Edwina AE, Koch BCP, Muller AE, Al Jalali V, Matzneller P, Zeitlinger M, Sassen SDT. Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers. *Eur J Clin Pharmacol.* 2023 Jun;79(6):775-787. doi: 10.1007/s00228-023-03477-5.

- 287) van Os W, Wulkersdorfer B, Eberl S, Oesterreicher Z, Schwabl P, Reiberger T, Paternostro R, Weber M, Willinger B, Zeitlinger M. Bacterial growth and ceftriaxone activity in individual ascitic fluids in an *in vitro* model of spontaneous bacterial peritonitis. *Front Pharmacol.* 2023 Mar 29;14:1124821. doi: 10.3389/fphar.2023.1124821.
- 288) Bergmann F, Gabler C, Nussbaumer-Pröll A, Wölfl-Duchek M, Blaschke A, Radtke C, Zeitlinger M, Jorda A. Early Bacterial Coinfections in Patients Admitted to the ICU With COVID-19 or Influenza: A Retrospective Cohort Study. *Crit Care Explor.* 2023 Apr 10;5(4):e0895. doi: 10.1097/CCE.0000000000000895.
- 289) Nora EP, Aerts S, Wittkopp PJ, Bussemaker HJ, Bulyk M, Sinha S, Zeitlinger J, Crocker J, Fuxman Bass JI. Emerging questions in transcriptional regulation. *Cell Syst.* 2023 Apr 19;14(4):247-251. doi: 10.1016/j.cels.2023.03.005.
- 290) Horvath LC, Bergmann F, Hosmann A, Greisenegger S, Kammerer K, Jilma B, Siller-Matula JM, Zeitlinger M, Gelbenegger G, Jorda A. Endovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: A non-inferiority meta-analysis of 6 randomised controlled trials. *Vascul Pharmacol.* 2023 Jun;150:107177. doi: 10.1016/j.vph.2023.107177.
- 291) Ullah S, Ursli M, Fuhr U, Wiesholzer M, Kussmann M, Poepl W, Zeitlinger M, Taubert M. Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis. *Perit Dial Int.* 2023 May 2:8968608231167237. doi: 10.1177/08968608231167237.
- 292) Salmanton-García J, Wipfler P, Valle-Simón P, Merakou C, Kopsidas I, Bethe U, Steinbach A, Spivak O, Součková L, Mendonça MA, Koniordou M, Hellemans M, Frías- Iniesta J, Davis RJ, Barta I, Azzini AM, Askling HH, Argyropoulos CD, Álvarez-Barco E, Akova M, Bonten MMJ, Cohen-Kandli M, Cox RJ, Flisiak R, Husa P, Jancoriene L, Koscalova A, Launay O, Lundgren J, Mallon P, Marques L, Naclér P, Ochando J, Pana ZD, Tacconelli E, Tóth K, Trelle S, van Damme P, Zaoutis TE, Zeitlinger M, Albus K, Stewart FA, Hofstraat SHI, Bruijning-Verhagen P, Cornely OA; VACCELERATE Consortium. Electronic address: trialsites@vaccelerate.eu. VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe. *Vaccine.* 2023 Jun 13;41(26):3915-3922. doi: 10.1016/j.vaccine.2023.05.006.
- 293) Jorda A, Bergmann F, Ristl R, Radner H, Sieghart D, Aletaha D, Zeitlinger M. Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study. *Clin Microbiol Infect.* 2023 May 25:S1198-743X(23)00252-5. doi: 10.1016/j.cmi.2023.05.028. Epub ahead of print.
- 294) 3: Jalali VA, Matzneller P, Pham AD, van Os W, Wölfl-Duchek M, Sanz-Codina M, Vychytil A, Reiter B, Stimpfl T, Zeitlinger M. Plasma and intraperitoneal pharmacokinetics of ceftazidime/avibactam in peritoneal dialysis patients. *Clin Microbiol Infect.* 2023 Jun 8:S1198-743X(23)00277-X. doi: 10.1016/j.cmi.2023.06.002. Epub ahead of print. PMID: 37301439.
- 295) Jorda A, Gabler C, Blaschke A, Wölfl-Duchek M, Gelbenegger G, Nussbaumer-Pröll A, Radtke C, Zeitlinger M, Bergmann F. Community-acquired and hospital- acquired bacterial co-infections in patients hospitalized with Covid-19 or influenza: a retrospective cohort study. *Infection.* 2023 Jun 16. doi: 10.1007/s15010-023-02063-2.
- 296) Bergmann F, Jorda A, Zeitlinger M. VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. *N Engl J Med.* 2023 Jun 22;388(25):2395. doi: 10.1056/NEJMc2305030.

Book chapters:

Zeitlinger M. Drug interactions. Springer. Current Topics in Clinical Pharmacology. Published 2010.

Zeitlinger M. Drug interactions. Springer. Current Topics in Clinical Pharmacology 2nd Edition. Published 2016.

Theuretzbacher U, **Zeitlinger M.** Antibacterial Distribution and Drug-Drug Interactions in Cancer Patients. Humana Press. Management of Infections in Cancer Patients. Published 2011

Feurstein T, **Zeitlinger M.** Microdialysis in lung: Monitoring of exogenous and endogenous compounds. John Wiley & Sons. Applications of Microdialysis in Pharmaceutical Science. Published 2011

Sauermann R, **Zeitlinger M.** Microdialysis in internal organs and tumors. Springer Science + Business Media. AAPS Microdialysis in drug development. Published 2012

Zeitlinger M, Couet W, Barth A, Derendorf H. Microdialysis in Antibiotic Research. Springer Science + Business Media. AAPS Microdialysis in drug development. Published 2012

Contribution to guidelines or position papers:

Antiinfektiva – Behandlung von Infektionen. Initiative Arznei & Vernunft. 2nd Edition, November 2010.

Scientific collaborator in the buildup of the infectious diseases-database „Infektionsnetz Österreich“ (www.infektionsnetz.at) of the Austrian Society of Antimicrobial Chemotherapy.

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper 2020 Intensive Care Med.

Research priorities towards precision antibiotic therapy to improve patient care 2022 Lancet Microbe.

Version 2.0 des Dokuments „Die COVID-19-Pandemie in Österreich: Bestandsaufnahme und Handlungsrahmen“, 2022